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Abstract 
 
The Hepatitis-C virus is the leading cause of chronic hepatitis. The host immune system 
identifies specific viral patterns, and induces an Interferon response. IFNs are known to 
suppress HCV replication in vitro, by the induction of antiviral responses mediated by 
Interferon stimulated genes (ISGs) and the current treatment regimen of IFN-α and 
Ribavirin has proven partly successful. 
However, HCV remains a poor inducer of interferon. This feature is attributed to the ability 
of the HCV proteins to cleave
1,2
 or successfully circumvent
3
 most proteins involved in the 
interferon pathway. IFN-independent antiviral mechanisms have been shown to exist as 
bypass mechanisms in the event of viral evasion of the IFN system. 
In this study, gene knock-out lines lacking key molecules involved in induction, reaction 
and amplification of type I IFNs as well as antiviral responses induced by alternative 
pathways was used to determine the role of the type I IFN system in the restriction of HCV 
replication. The data provided here indicate the novel antiviral functions of Interferon 
regulatory factors (IRFs) and interferon stimulated genes (ISGs) in limiting HCV 
replication in mouse cells. Mouse cells with a competent interferon signalling system did 
not permit replication of HCV whereas cells with individual defects in the type I interferon 
response, IRF-3, STAT-1 and the ISG PKR permitted detectable levels of replication. 
However, replication was observed in cells with defective IRF-5, IRF-7 and IRF-1 only in 
the absence of a type I interferon response.  
These results argue, that lesion of these genes weaken such IFN-independent defences to 
the extent that HCV replication is detectable upon neutralization of secreted IFN. 
Therefore, we conclude that in WT MEFs, IFN-dependent and independent mechanisms 
contribute to the control of HCV replication, and that IFN-independent defences are 
mediated through IRF-5, IRF-7, IRF-1 and PKR. Interestingly, IFNAR
-/-
, IRF-3
-/-
 and 
STAT1
-/- 
cells showed no further increase in replication of the subgenoimc replicon upon 
type I IFN depletion which could be based on lower expression levels of IRFs
4,5
. This is 
compatible with the current view that these factors are essential for the IFN-mediated 
antiviral activity. Taken together, these data show that apart from the predominant type I 
IFN response, IFN-independent antiviral effects are involved in restricting HCV 
replication in mouse fibroblasts.  
Similarly, data from primary mouse hepatocytes indicate that in addition to the type I 
interferon responses, other interferons such as type III interferon may also exert antiviral 
effects.  
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1. Introduction 
 
The hepatitis-C virus (HCV) affects approximately 200 million individuals worldwide. It 
was in 1990 that Houghton and colleagues had identified the causative agent of the elusive 
non-A non-B hepatitis (NANBH) to be a characteristically and pathologically different 
virus. This virus was then termed as the ‘Hepatitis-C’ virus. Today, decades after its 
identification, HCV related morbidity and mortality has risen to pandemic proportions. 
Although current treatment regimes of pegylated IFN and ribavirin has proven largely 
successful, not all treated patients attain viral clearance. Therefore, the need for a suitable 
vaccine and more effective treatment measures are pressing.  
1.1 Overview of Hepatitis-C virus 
Non-A, Non-B viral hepatitis was first identified in 1975 through serological studies that 
tested negative for Hepatitis-A and Hepatitis-B viruses
6
. Prior to its identification and 
classification, NANBH was known to be the etiologic agent of transfusion-derived 
hepatitis, associated frequently with significant morbidity and mortality
7
. The first viral 
sequences of the pathogen were identified in 1989 by screening lambda phage 
complementary DNA expression libraries developed from nucleic acids extracted from 
NANBH infected chimpanzees and screening them against serum derived from a NANBH 
patient 
8
. This causative agent of the Non-A, Non-B viral hepatitis regarded to cause 
serious illness was discovered to be an RNA virus of approximately 9.6 kb and renamed 
Hepatitis-C virus (HCV). Since its discovery, scientific research on HCV has come a long 
way. Known to cause both acute and chronic hepatitis, with the latter often leading to 
fibrosis, cirrhosis and hepatocellular carcinoma, Hepatitis-C infection has been recognized 
as a global health concern affecting nearly 3% of the world population. 
1.1.1 Taxonomy and Genotypes 
HCV has been classified as the sole member of the genus Hepacivirus within 
the Flaviviridae family.   
Differences in the genetic variability of HCV occur at several levels. Firstly, owing to the 
highly heterogeneous genome of the Hepatitis C virus, it is classified into 7 different 
genotypes 
9
. HCV genotypes 1 and 2 are relatively globally distributed whereas genotype 3 
is prevalent in South East Asia and India; Genotype 4 is found in the African continent and 
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in the middle East ; Genotype 5 is common to South Africa and genotype 6 is predominant 
in South East Asia 
10,11
. Finally, in an attempt to adapt to the host and evade the immune 
system, HCV diverges significantly over time within an infected individual giving rise to 
several ‘quasispecies’. 
Genotypes 1a and 1b are relatively more resistant to treatment with IFN-α as compared to 
genotypes 2a, 2b and 3a. Since treatment response has been shown to be associated with 
viral genotype, the identification of the genotype helps determine treatment regimen and 
dose and predict treatment outcome 
12
.  
1.1.2 Prevalence and Risk factors 
An estimated 170-300 million people are infected with Hepatitis-C 
13
. However, the extent 
of disease transmission  on a global scale is not well established, because acute infection is 
generally asymptomatic associated with mild flu-like symptoms making many infections 
going unaccounted for and also because estimates from the developing world are largely 
variable or not available 
14
. 
Today, the major cohort of HCV infected individuals belong to the injecting drug user 
(IDU) category. Other common sources of infection include percutaneous exposure to 
blood through cosmetic procedures and cultural practices like tattooing, acupuncture, body 
piercing, circumcision etc 
15
. Nosocomial transmission of the virus is possible and includes 
needle-stick injuries among health care workers, infection during surgery or dental 
treatment, and other medical procedures
15,16
.   
Since diagnosis is largely elusive and treatment outcome is variable, the need for vaccine 
development is pressing. 
1.1.3 Pathogenesis and clinical manifestations 
One of the salient features of HCV infection is its propensity to establish a persistent 
infection ultimately leading to hepatic disease. Pathogenesis differs between acute and 
chronic Hepatitis-C 
17,18
. The incubation period for acute HCV infection is from 2-10 
weeks, with an average incubation phase of six to seven weeks
19-22
.  60-70% of patients 
infected with acute HCV are asymptomatic and resolve infection; 20-30% present with 
jaundice; and 10-20% have nonspecific symptoms such as loss of appetite, fatigue, nausea, 
weight loss and abdominal pain or discomfort 
23,24
. Elevations in liver enzyme levels are 
analyzed to assess the extent of hepatic injury. Due to the late onset of anti-HCV 
antibodies, and non-apparent symptoms, acute Hepatitis C often goes unrecognized. Of all 
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the infected patients, approximately 80% progress to chronic hepatitis. The persistence and 
detection of HCV RNA 6 months after the acute phase is said to be characteristic of 
chronic hepatitis. 
1.1.4 Standard mode of therapy 
Acute hepatitis-C is resolved if asymptomatic or cured in most cases if diagnosed
25,26
, 
whereas treatment of chronic hepatitis-C is largely variable, effective in only half the 
patient population. Therapy of chronic hepatitis-C has evolved from IFN alpha (IFNα) 
monotherapy to the use of a polyethylene glycol modified form, called pegylated IFNα 
(pegIFNα) with increased biological half-life, administered together with the nucleoside 
analogue ribavirin. This combination therapy has been the standard mode of treatment 
since 2001 ensuing in the best case, a sustained virological response (SVR) rate of 46–
55%
27-29
. Due to the added advantage of an extended half life, patients need be 
administered IFN alpha only once a week as compared to unmodified IFN alpha. 
The aim of therapy is sustained virological response as assessed by PCR for serum viral 
load (VL) after 4 and 12 weeks of therapy.  
Recent developments in the understanding of HCV, particularly in its biology have enabled 
us to appreciate the interest in antiviral strategies directed against specific proteins of the 
virus. DAAs (Direct Acting Antiviral) are inhibitory molecules directed against proteins 
that have important enzymatic or structural functions in virus propagation. Protease 
inhibitors boceprevir and telaprevir have been FDA approved for treatment when 
administered in combination with peg-IFN-α and ribavirin. Many other drugs are currently 
in various phases of pre-clinical trials. 
The lack of fidelity of the RNA dependent RNA polymerase (RdRp) with respect to its 
proof reading capacity combined with high replication rates 
30
 results in the generation of a 
large number of quasi-species. This pool of variants might naturally comprise strains that 
are more resistant to drugs. Additionally, under specific drug pressure, the risk of selecting 
for a dominant resistant strain is high 
31
 and is therefore considered a matter of grave 
concern. The ideal drug must therefore decrease viral load but maintain an increased 
barrier for resistance, and be effective pan-genotypic, and across isolates and escape 
mutants.  
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1.1.5 Vaccines 
Currently, there exists no available vaccine to prevent HCV infection. The development of 
a vaccine against HCV is challenging owing to the presence of diverse genotypes and 
quasispecies expressing epitope heterogeneity 
32
. However, spontaneous clearance of the 
virus, the development of neutralizing antibodies and adaptive responses against the virus 
in infected humans
33,34
 lend hope to the development of an effective vaccine.  
Hence, further research aiming at identifying a target viral protein that can be used in 
vaccines is warranted. In parallel, due to the large inter- individual variation in response to 
HCV infection, studies on host responses to infection are required. 
 
1.1.6 Viral tropism of HCV 
HCV typically infects hepatocytes but data also confirm detection of HCV RNA in B 
lymphocytes as well as in the CNS. HCV primarily infects hepatocytes and the ensuing 
cellular insult results in various pathological conditions characteristic to HCV such as 
elevated AST/ALT and bilirubin levels. This eventually leads to severe irreversible 
conditions such as fibrosis, cirrhosis, and HCC.  
Although HCV has been regarded as hepatotropic, various reports have detected HCV 
RNA in PBMCs as well as in the CNS. Various immune defects as well as lymphomas 
observed in patients chronically infected with HCV have been correlated to the infection of 
PBMCs.  
Although the presence of HCV has been detected in PBMCs and is hypothesized to be the 
basis of occult infections, whether infection can occur in these reservoirs is still unclear. 
Similarly, the HCV-associated neuropathogenesis has been attributed to the detection of 
HCV RNA present in the post mortem brains of HCV infected patients corroborated by the 
expression of all entry factors required for HCV entry into the brain endothelium
35
.  
HCV has been shown to replicate in a variety of cell lines of non-hepatic origins such as 
293 cells, T 
36
 and B 
37
 cells, human brain endothelial cells 
35
, HeLa cells 
38
 as well as 
Human embryonic kidney cells 
39
. Also, HCV has been observed to replicate in cells of 
non-human and non-primate origin such as mouse fibroblasts
40
. 
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1.1.7 The Genome organization of HCV 
The HCV genome is a 9.6 kb long single stranded RNA strand. It comprises the genetic 
codes for the structural as well as the non-structural proteins and is flanked by the two 
conserved 5’ and 3’non translated regions (NTRs). The 5’ NTR is essential for viral 
translation and replication. The 5’NTR region possess the homologous IRES element 
pivotal in cap-independent translation. The 3’ UTR has a tripartite structure and is 
important for HCV replication. The 3’NTR is a well defined structure comprising a 
variable region, followed by a poly (U/UC) tract and a conserved 3’ X tail sequence.  
The HCV polyprotein is processed by both cellular and viral proteases and peptidases to 
form individual protein sequences. E1 and E2 are envelope proteins highly glycosylated 
and interact with the host cell entry receptors such as cluster of differentiation 81 (CD81), 
scavenger receptor class B type I (SR-B1), and occludin (OCLN) mediating cellular entry. 
The non-structural proteins play important roles in replication, virus processing and have 
also evolved to antagonize the host response. 
5’NTR 3’NTR
IRES
C E1 E2 3 5B5A4B2 4
Ap
7
C E1 E2 3 5B5A4B2 4
Ap
7
Signal peptide peptidase Signal peptidase NS2/3 protease NS3/4A protease
Structural Non-structural
Translation
Processing
 
Figure 1: Genome organization and processing of HCV 
A schematic representation of the HCV genome. The 5' and 3' NTRs are non translated regions 
important in replication of HCV, the endogenous IRES element aids in cap-independent translation. 
The structural proteins E1 and E2 are the envelope proteins whereas the Core protein codes for the 
capsid structure. Protein p7 is an ion-channel protein. The non-structural elements NS2, NS3 and 
NS4A are proteases helping in post translation auto-cleavage of the polypeptide. NS4B aids in 
replication complex formation. NS5A comprises of an ISDR and NS5B is the RNA dependent 
RNA polymerase. Proteinases and peptidases involved in processing of the polyprotein are 
indicated by arrows.  
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The viral protein p7 is an ion channel protein that is indispensable to virus production. 
NS2 is also important for virus production but is dispensable for HCV replication. The 
NS2/3 cyteine protease effectively cleaves the NS2 and the NS3 proteins into fully 
functional individual proteins. The NS3 protein is a serine protease which in combination 
with stabilizing factor NS4A cleaves the junctions between itself, NS5A and NS5B. The 
NS3/4A also effectively cleaves important adaptors of the IFN response such as the MAVS 
and the TRIF proteins. The NS4B is an integral membrane protein that is localized at the 
replication complexes called ‘membranous web’. These organelles are complexes of non-
structural proteins that act as scaffolds for HCV replication. The NS5A has an ‘Interferon 
Sensitivity Determining Region (ISDR)’ and mutations in this region are associated with 
IFN sensitivity that is characteristic to genotypes. 
The NS5B is the viral RNA dependent RNA polymerase (RdRp) without which the virus is 
incapable of replication.  
 
1.1.8 HCV life cycle  
The HCV life cycle progresses through multiple distinct stages. Once in the blood stream, 
the virus travels to the highly vascularized liver.  
The initial step of cellular entry is aided by the binding of the E1/E2 envelope 
glycoproteins to specific receptors on the cell surface. Receptor binding leads to 
internalization of the clathrin-coated virus particle by endocytosis followed by fusion to an 
endosomal compartment. The surface receptors required for HCV entry include tight 
junction proteins like Occludin 
41
, SR-B1 
42
 and Claudin 
43
 as well as CD81, a tetraspanin 
family protein 
44
. Studies have indicated the role of low density lipoprotein receptor 
(LDLR) 
45,46
, DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing 
non-integrin) as well as C-type lectin domain family 4 member as receptors for HCV 
through their interaction with E2. Fusion of the clathrin-coated vesicle to the endosome 
results in acidification inducing the release of the single stranded, positive sense viral RNA 
into the cytoplasm of the infected cell. Once released, the viral RNA serves as a template 
for further replication as well as cap-independent translation. The translation machinery of 
the HCV genome employs the HCV-IRES 
47
 element coded by the 5’ non-translated 
region. The HCV IRES directly binds the 40S ribosomal subunits and subsequently  
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Figure 2 : The HCV life cycle 
The HCV infects a cell through 1) interactions between the glycoprotein on their surface with the 
tight junction and other receptors on the cell membrane. 2) the virus is endocytosed into the cell 
following which 3) it uncoats and releases its genetic material. Here, the viral RNA undergoes 4) 
translation and 5) replication. 6-8) RNA processing, cellular trafficking and maturation of the virus 
particle finally results in virion release 
48
.  
 
 
recruits eukaryotic initiation factor (eIF) 3 followed by the ternary complex of Met-tRNA–
eIF2–GTP to form a 48S intermediate, before forming an active 80S complex. Following 
translation, the polypeptides undergo processing by host signal peptide peptidases. Soon 
after translation, the replication complex comprising the viral genome, host and viral 
proteins are formed. Replication is initiated at specific membrane-derived organelles called 
‘membranous webs’ 49 where the RNA dependent RNA polymerase begins replicating the 
viral genome. Since the RNA dependent RNA polymerase (RdRp) is devoid of proof 
reading activity, the resulting progeny are error-prone. The RNA thus replicated are either 
used as templates for further replication, translation or are simply packaged into capsids 
forming virions that are exocytosed and now capable of infection. The lack of fidelity of 
the RdRp gives rise to several variants of the virus termed ‘quasi-species’. The continuous 
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turn-over of variant strains, although not always ‘fit’ allows for the selection of strains with 
epitopes capable of evading immune responses. 
 
1.2  The Type I IFN Response 
The type I IFNs are induced in response to viral infections. The viruses are recognized as 
non-host due to specific pathogen associated molecular patterns (PAMP). The receptors 
that sense these ‘signatures’ exhibit organelle specific localization. Some of these receptors 
are discussed below. 
 
1.2.1 Viral sensors 
RLRs  
Although the cell membrane and the endosomal vesicles are guarded against pathogen 
attack by TLRs, certain pathogens can uncoat themselves in the cellular cytoplasm 
escaping detection by the TLRs. This situation is avoided by the presence of specific 
cytoplasmic sensors that recognize pathogen signatures. One such receptor is the family of 
RIG-I-like receptors (RLRs) that constitute RIG-I, MDA-5 and the negative regulator 
LGP-2. 
RIG-I and MDA5 consist of a DexD/H box RNA helicase domain, two N-terminal 
caspase-recruitment domains (CARDs), and a C-terminal repressor domain all of which are 
important in a strictly regulated signalling process. Unlike RIG-I and MDA-5, LGP-2 has 
no CARD domain and acts in regulating the RIG-I/MDA-5 signalling process. RIG-I and 
MDA-5 although similar in their location and functions have relatively distinct substrate 
specifications. RIG-I recognizes ssRNA of defined lengths along with 5’ triphosphates 
terminal regions on mRNAs, resulting from viral replication, or from RNaseL mediated 
cleavage products of the virus and also by artificially introduced products of in vitro 
transcription
50,51
. The MDA-5 recognizes comparatively long poly (I:C) regions and viral 
genomic dsRNA. Apart from the differences in genetic elements, the receptors also 
recognize different viruses
52
. Where RIG-I recognizes paramyxoviruses, MDA-5 is 
important in recognition of picornavirus. Although similar in their action, RIG-I recognizes 
Japanese Encephalitis virus (JEV) and HCV whereas West Nile virus and Dengue virus; 
albeit belonging to the Flaviviridae family are both recognized by MDA-5
53
. 
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TLRs  
Cellular surveillance on the membrane and the endosomal compartments are carried out by 
TLRs. TLRs are proteins containing an extracellular domain of leucine-rich repeats (LRRs) 
and a cytoplasmic TIR (Toll/IL-1R homology) domain 
54
. 13 TLRs have been recognized 
in humans. The reason for their diversity and differential localization is to enable the cell to 
detect a wide array of pathogens differing in structural as well as genetic composition. 
TLRs localized on the cell membrane (TLRs 1, 2, 4, 5 and 6) protect against extracellular 
pathogens whereas TLRs on the endosomal compartments (TLRs 3, 7/8 and 9) help defend 
against pathogens that are taken up within the cell. TLRs 2, 3, 4, 7, 8, and 9 have been 
reported to be important in the detection of viral components
55
. TLR2 and TLR4 are best 
understood in the context of recognizing Gram-positive (lipoteichoic acid) and Gram-
negative bacteria (lipopolysaccharide) respectively, but are also important viral sensors. In 
the case of TLR2, the difference in the outcome of viral or bacterial detection lies in the 
internalization of the receptor post recognition. Upon detection of a virus, the TLR2 is 
immediately internalized leading to the activation of the NFκB dependent inflammatory 
pathway as well as the IFN dependent antiviral pathway whereas in a bacterial attack only 
the inflammatory response is activated.  
TLR3 is activated by dsRNA (dsRNA virus or replicative intermediates) and its synthetic 
surrogate polyinosinic:polycytidylic acid (polyI:C). The endosomally localized TLR7/8 is 
known to recognize ssRNA as well as guanosine- and uridine-rich ribonucleotides. TLR9 
recognizes the (cytidine-phosphate-guanosine) (CpG) motifs on the pathogen genome and 
is therefore important in the detection of DNA viruses such as HSV
56
.  
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Figure 3: Signalling pathways of pattern recognition receptors 
Cytosolic RIG-I as well as the endosomal TLRs play an important role in recognizing 
specific pathogen patterns. This results in the downstream activation of cellular adaptor 
molecules such as MyD88 and TRIF. The activation is relayed to the nucleus and leads to 
the induction of an interferon and an inflammatory response. 
 
 
1.2.2 Signalling of Viral Sensors  
The induction of an immune as well as an inflammatory response is the result of a series of 
synchronized cascades initiated by the detection of a pathogen eventually leading to the 
induction of IFN stimulated genes and proinflammatory cytokines. Since pathogens can 
enter cellular cytoplasm through endosomal vesicles, pattern recognition receptors are 
specifically distributed within a cell. This organelle specific localization enables detection 
of a wide range of pathogen signatures. Of the Pathogen Recognition Receptors (PRRs), 
the most extensively studied are the Toll-like receptors (TLR). The TLRs are Type 1 
transmembrane proteins signal between endosomes and the cellular cytoplasm. TLRs are 
located on the plasma membrane as well as in the endosomal vesicles. This localization 
enables efficient detection of viral particles present in the extracellular matrix as well as 
the recognition of viral genome released within the endosomes during viral uncoating. 
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Once the virus is released into the cytoplasm, they are patrolled by the RIG-I like receptors 
(RLR family), the nucleotide oligomerization domain-like receptors, as well as DNA 
sensors such as the members of the AIM2 family.  
 
RLR Signalling  
Signalling through RIG-I like receptor depends on the CARD-CARD interaction between 
the receptor and the mitochondrial antiviral signalling [MAVS] (also known as CARD 
adaptor inducing IFN-β [Cardif], mitochondria-located adaptor molecule IPS-1 and virus-
induced signalling adaptor [VISA]). Upon recognition of specific pathogen signatures, 
RIG-I/ MDA5 undergo conformational changes that permit close interaction with the 
CARD domain of MAVS. This interaction leads to the assembly of proteins on the 
mitochondrial surface that subsequently triggers the induction of downstream proteins. 
This complex activates TBK1 and IKKα/β that phosphorylates IRF-3 and IRF-7, and 
induces an IFN response. Additionally, it also activates the kinase activity of the IKKγ 
complex which results in NF-κB activation.  
 
TLR Signalling  
The primary role of TLR molecules is to recognize pathogen signatures and induce host 
responses against them. To do so, they require adaptor proteins that relay information from 
the localized TLRs into the nucleus. The adaptors that TLRs use are the myeloid 
differentiation factor 88 (MyD88), MyD88-adaptor-like (Mal), TIR domain-containing 
adaptor inducing IFN-β (TRIF), and TRIF-related adaptor molecule (TRAM). The use of 
one or more of these adaptors leads to the induction of a distinct and specific immune 
response. TLR3 activates downstream targets through adaptor protein TRIF whereas 
TLR7/8 and TLR9 induce antiviral responses specifically through MyD88. TLR2 has been 
shown to signal through MyD88 via Mal and TLR4 can signal through MyD88 as well as 
through TRIF.  
 
1.2.3 Induction of Type I IFNs 
The IFNs are critical mediators of an antiviral response. The IFNs, comprising type I (IFN-
α (alpha), IFN-β (beta), IFN-κ (kappa), IFN-δ (delta), IFN-ε (epsilon), IFN-τ (tau), IFN-ω 
(omega), type II (IFN-γ), and type III (IFN-λ 1,2 and 3), play a crucial role in the host 
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immune response. The type I IFNs are induced during an infection. These pleiotropic 
cytokines act in an autocrine and paracrine manner to activate host cell antiviral responses 
and also alert the surrounding cells of the viral invasion. As described previously, upon 
detection of specific pathogen signatures (PAMPs) by Patter Recognition Receptors PRRs, 
transcription factors like IRF-3 are activated. Transcriptional activity of IRF-3 is induced 
by virus and dsRNA-stimulated, C-terminal phosphorylation. The activated IRF-3 
translocates to the nucleus and together with NF-κB, AP-1, and the nuclear architectural 
protein HMG-I(Y) (high mobility group protein [non histone chromosomal] isoform I and 
Y) assemble into an enhanceosome complex on the IFN-β promoter. This results in 
recruitment of specific molecules, such as the co-activators CBP and/or p300 to initiate 
transcription and synthesis of IFN-β 57-59. 
 
IRF-3 activation
IFN signalling
IFN-β
production
ISG expression
 
Figure 4: Type I IFN production and signalling 
Detection of pathogen by pathogen recognition receptors (TLRs, RIG-I) leads to the activation of 
downstream adaptor molecules eventually leading to the activation of IFN and ISGs. IRFs are 
factors that relay activation signals from the cytoplasmic or endosomal PRRs to the nucleus. IFN-
/β bind to the IFNAR receptor which leads to the activation of the Janus kinases Tyk2 and Jak1 
which activates STAT1 and STAT2 proteins. STAT1 and STAT2 form a complex with IRF-9 
called the ISGF3 which binds to ISRE elements of ISG e.g. IRF-7. IRF-7 is activated and induces 
IFN s which leads to the amplification of the IFN response. 
 Adapted from Gale et al. Nature 2005 
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IRF-3 displays constitutive expression in the cytoplasm in most cell types, whereas IRF-7 
is only expressed upon induction by IFNs, an expression pattern that is also largely cell 
type specific
60
. Therefore, activation of IRF-3 allows instant production of IFN-β upon 
viral invasion omitting the need for de novo synthesis. The further amplification of this 
loop depends on the production of IFN-β and the subsequent binding to the IFN-α/β 
receptor. This second loop requires activation of transcription factors such as IRF-9 and 
other molecules such as the (Signal Transducers and Activators of Transcription) STATs
61
. 
In addition, both IRF-3 and IRF-7 possess the potential to either homodimerize or 
heterodimerize with each other, permitting activation of distinct IFN genes
61,62
. 
The preferential activation of the ifn-β promoter by IRF-3 is due to its limiting DNA 
binding potential 
62
. In comparison, IRF-7 has a broader DNA binding specificity and is 
capable of inducing both IFN-β and IFN-α efficiently, thereby contributing to the 
amplification of the primary IFN response. Thus, the differential gene expression patterns 
induced by IFN-α/β is attributed to the differential expression and binding specificity of the 
IRFs. 
 
1.2.4 Antiviral Signalling of Type I IFNs  
IFN induction leads to specific autocrine and paracrine binding of IFN to its receptor 
resulting in stimulation of a wide array of genes essential for antiviral defense. These steps 
are orchestrated by strict and complex mechanisms. Upon IFN receptor activation, 
downstream Janus kinase (JAK) and Tyrosine Kinase (TYK2) phosphorylate STAT 
proteins at specific serine and tyrosine residues. Thus activated, the STAT proteins can 
now assemble into a complex along with IRF-9 and actively translocate into the nucleus. 
Once in the nucleus, this complex called the (Interferon stimulated gene factor 3) ISGF3 
binds to the promoters of the ISGs thereby transcribing them. ISG activation can also result 
from the binding of STAT1 homodimers to the IFN-γ activated sites (GAS) elements. The 
induction and activation of antiviral proteins renders the cell capable of limiting viral 
spread and elimination of virus-infected cells.  
In hepatocytes, double-stranded RNA (dsRNA) triggers two independent pathways of host 
defense through retinoic acid-inducible gene I (RIG-I) and Toll-like receptor 3 (TLR-3) 
63
. 
The recognition of Pathogen Associated Molecular Patterns (PAMP) results in the rapid 
induction of IFN-alpha and IFN-beta and subsequent activation of intracellular signalling 
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events leading to expression of IFN-stimulated genes (ISGs) that are central to antiviral 
responses
64
. 
Expression profiles of IFN-stimulated genes obtained from livers of patients with Chronic 
Hepatitis-C as well as chimpanzees with experimental acute Hepatitis-C were shown to be 
upregulated 
65,66
. However, elevated ISG levels are not an indication of chronic infection as 
some chronically infected patients show little to no upregulation 
66
, despite comparable 
levels and duration of virus infection.  
IRF3 (IFN regulatory factor 3), a highly regulated transcription factor constitutively 
expressed in the cytoplasm in a latent inactive form, plays a key role in regulating the 
synthesis of IFN-β (17).  
Some of these antiviral proteins include Protein Kinase R (PKR), 2’,5’oligoadenylate 
synthase (2’,5’-OAS), myxovirus-resistance proteins (Mx), ISG15, ISG56, TRIM79 alpha 
and dsRNA-dependent adenosine deaminase (ADAR). 
The RNA-dependent protein kinase R (PKR), a serine/threonine kinase is stimulated 
during viral invasion. PKR, when activated upon dsRNA binding of viral genomes or 
replication intermediates gets autophosphorylated after which it subsequently 
phosphorylates the eukaryotic translation initiation factor-2 (eIF-2).  
The role of eIF-2 in the initiation of peptide synthesis in mammals is directed to deliver 
Met-tRNAi to the 40S ribosome. eIF-2 composed of three subunits (α, β, and γ) binds to 
the Met-tRNAi in a GTP-dependent manner to form a ternary complex which attaches to 
the 40S subunit of the ribosome. Upon delivery, eIF-2 is released from the initiation 
complex. eIF-2 activity is autoregulated by phosphorylation of the α subunit at position 
S51. eIF-2α phosphorylation, results in an exaggerated affinity of eIF-2 for eIF-2B leading 
to competitive inhibition of eIF-2B and an immediate arrest of  translation initiation 
67
.  
Similarly, 2’,5’-OAS, another IFN-inducible gene makes use of a cellular endonuclease 
RNaseL. Upon activation of 2’5’-OAS by dsRNA or replication intermediates ATP gets 
converted to an adenosine oligomer 2’5’-A which then configures latent RNaseL to its 
active form
68
. Cleavage products of this endonuclease can also trigger RIG-I 
69
 thus further 
increasing the activity of RNase L.  
 
1.2.5 Antiviral Signalling of type III IFNs 
Type I IFNs are important in directing antiviral immunity. However, another family of 
molecules was identified that had properties similar to type 1 IFNs but were structurally 
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and genetically distinct. These IFNs were referred to as the type III IFNs or broadly IFN- 
λs. Unlike IFN-α which is expressed by all nucleated cells, response to IFN-λ seems to be 
restricted to epithelial cells. Tissues rich in epithelial content such as intestines, lungs and 
skin were found to be more responsive to IFN-λ. Evolutionarily, IFN-λ is said to have been 
evolved to protect mucosal and epithelial cells from pathogen insult. Structurally, the IFN-
λ family of cytokines is similar to the Il-10 receptor family. There are 3different genes that 
encode 3 different forms of IFN-λ: IFN-λ1, IFN-λ2 and IFN-λ3.  
The triggers for IFN-λ are similar to that of the type 1 IFN and largely stimulus dependent. 
The type III IFN receptor is composed of the IL-10Rβ subunit and the IL28Rα that are 
important for signal transduction. IFN-λ receptor activation leads to the activation of 
STAT-1 and STAT-2 molecules that complex with IRF-9/p48 forming the ISGF3 complex. 
This induces the transcription of several hundred IFN stimulated genes. The ISGs induced 
by type III IFN was shown to be similar to that induced by the type 1 IFNs. Therefore, 
similar to type1 IFN, type III IFNs have been shown to possess antiviral, anti-proliferative 
and immune modulatory functions. A recent study on chimpanzees has described the 
dominant role of IFN-lambda over type 1 IFN in the induction of downstream ISGs in the 
hepatocyte microenvironment 
70
.  
  
1.2.6 Virus host interactions 
The drastic variations in HCV pathogenesis is largely inter-individual dependent. These 
variations occur at several levels during the recognition and interaction of the virus by the 
host which ultimately defines disease outcome. Upon infection of the liver, IFNs are 
produced that result in the induction of an antiviral state aiding in limiting HCV replication 
71
. Therefore, it is not surprising that HCV has evolved several strategies to evade the IFN 
system 
1,2
. In the liver, the innate immune system after having recognized the virus also 
directs the adaptive immune response. The Kupffer cells of the liver play an important role 
in pathogen clearance and also recruit NK cells and T cells to the site of infection 
72-74
. 
While NK cells produce IFN-gamma (IFN-γ) to limit viral replication, activated DCs 
present antigens and produce type 1 IFNs aiding in restricting HCV replication. However, 
the specific roles of the cellular immune response in HCV infection are largely elusive. 
The role of T cells in viral pathogenesis is relatively well established
75
. During the acute 
phase, the effector function of CD8+ T cells and the helper CD4+ T cells in the liver and 
the peripheral blood serve in clearing the virus. The importance of these two cell types is 
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further corroborated by increased viremia observed in experimentally infected 
chimpanzees with depleted T cells. However, during chronic infections the CD4+ T cell 
responses were absent and the CD8+ T cell responses were observed to be dampened. The 
reasons for T cell dysfunction have been attributed to the expression of programmed death 
1 (PD-1); a T cell inhibitory molecule, to the suppression of T regs 
76
, and the increased 
secretion of interleukin (IL)-10 
77
.  
 
1.2.7 Evasion of the host immune system by HCV 
Pathogen entry into cells is recognized by the cellular host factors that recognize and 
stimulate an anti-microbial response. When HCV infects hepatocytes, several of its 
pathogen signatures are recognized by the pattern recognition receptors (PRR). The 3’NTR 
of the HCV genome harbours a poly(U/UC) tract which in addition to the 5’-PPP region is 
reported to be recognized by the RIG-I receptor. Similarly, the TLR3 recognizes dsRNA 
formed as a replication intermediate. Activation of PRRs leads to the induction of antiviral 
as well as proinflammatory cellular responses.  
HCV like most viruses has evolved mechanisms to evade such an immune attack. Several 
protein components of HCV have evolved to actively counteract key regulatory molecules 
in the innate immune signalling pathway. One such viral component is the NS3/4A viral 
protease that cleaves adaptor proteins TRIF and MAVS thereby stunting the downstream 
TLR3 and RIG-I signalling respectively. Inhibition of NS3 function is observed to restore 
RIG-I signalling. The two recently approved antiviral drugs Boceprevir and Telaprevir 
both target the NS3 protease. The induction of (suppressor of cytokine signalling) SOCS3 
is upregulated leading to compromised IFN signalling. Similarly, HCV replication induces 
protein phosphatase 2A (PP2A), which results in increased binding of STAT1 to its 
inhibitor PIAS1 (protein inhibitor of activated STAT1). Apart from the inhibitory effects 
exerted directly by the HCV proteins, HCV has also evolved strategies to indirectly alter 
the immune response. The upregulation of USP18 is said to interact with IFNAR and 
inhibit the subsequent JAK/STAT signalling, it is corroborated by evidence of increased 
USP18 in livers of patients with chronic HCV. Increased host protein kinase PKR, results 
in phosphorylation of the eukaryotic initiation factor eIF-2α that suppresses cellular 
translation thereby blunting the antiviral response. This mechanism leaves the HCV 
translation machinery unaffected as the virus translation can proceed through IRES 
mediated ribosome scanning. 
INTRODUCTION 
18 
 
Taken together, HCV has evolved not only its genome to directly restrict HCV replication 
mechanisms but has also altered the host response pathways to aid in increased HCV 
replication.  
 
1.3 HCV model systems 
1.3.1 Cell culture models 
The establishment of experimental model systems for HCV has been practically 
challenging. Although the HCV genome has been readily available since 1989, cell culture 
systems as experimental models were successfully developed only much later. Till date, 
the chimpanzee remains the only animal model susceptible to HCV infection although 
small rodents and dogs as model systems are emerging.  
Various cell culture systems for efficient replication and infection have been developed, 
the first ever reported case of HCV replication being in 1999 with the discovery of the 
subgenomic replicon system
78
. The subgenomic replicon is a bicistronic RNA in which 
sections of the HCV genome encoding the structural and part of the nonstructural proteins 
were replaced by the neomycin phosphotransferase (NPT) gene driven by the homologous 
IRES in the 5’UTR, and a second heterologous EMCV-IRES (from Encephalomyocarditis 
Virus) translating the non-structural proteins NS3–5B.  
Since then, the replicon system has been modified in ways that have allowed for the 
insertion of variations in the marker cassettes, the addition of self-cleaving ribozyme 
79
 
chimeric replicon systems J6JFH1
80
 etc. The system has been widely used for analysis of 
HCV RNA and proteins, biochemical and structural characterization of the viral replication 
complex, for high throughput screening for drug discovery, and determination of antiviral 
resistance. 
The Con1 (encoding genotype 1b) replicon system was a major breakthrough, until it was 
discovered that the strain resisted virus production in cell culture and productive 
replication in chimpanzees. It was hypothesized that either the cells lacked the required 
machinery to drive virus production or that the acquired mutation that enhanced replication 
potential had rendered the clone incapable of forming infectious virions in culture.
81
.  
This unexpected setback was soon overcome by the discovery of the JFH1 strain obtained 
from a patient with Japanese Fulminant Hepatitis (JFH1). The JFH1 strain had an inherent 
replication potential manifold higher than the Con1 strain and replicated in hepatic as well 
as non-hepatic cell lines without the need for adaptive mutations
38,82
. This discovery then 
INTRODUCTION 
19 
 
became the basis of infectious particle production in cell culture wherein in vitro 
transcribed RNA transfected into Huh7 cells gave rise to infectious HCV cell culture 
particles referred to as HCV cc.  
The replicon system has since then been expanded to include virus production systems 
from genotypes 1a (H77) and 1b (Con1) as well as various reporter systems that have been 
established for microscopic analysis
83,84
. 
 
1.3.2 Animal models 
The chimpanzee is currently the only animal model susceptible to HCV infection. 
Although several of the advancements in the field of HCV from its discovery to the host 
response to the virus is attributed largely to chimpanzee studies, the animal model is 
expensive, and is restricted due to ethical constraints and limited accessibility. 
Advancements in rodent models have led to the development of several models such as 
immunotolerant rat models with transplanted human liver cells and the HCV trimera model 
wherein irradiated mice were reconstituted with bone marrow cells from severe combined 
immunodeficient (SCID) mouse and transplanted with HCV-infected liver cells
85
. 
However, these models suffer due to low viremia, limiting their use in drug efficacy 
studies. 
Another significant advancement in the development of a mouse model for HCV 
propagation was the SCID/albumin-urokinase type plasminogen activator (Alb-uPA) 
86
 
mouse. This mouse model is based on a SCID background transplanted with normal human 
hepatocytes. It alleviates several disadvantages plaguing models that had been developed 
before. With reduced liver toxicity owing to the expression of the Alb-uPA transgene and 
its immunocompromised background, the SCID/Alb-uPA mouse enables generation of 
high titres of virus production upon inoculation of HCV patient serum. However, due to 
the immune compromised background, the elucidation of the immune responses against the 
virus is impossible. 
Difficulties encountered in culturing HCV in cell lines of varied origins strongly suggests 
the involvement of several viral and host cellular factors in the replication and completion 
of the HCV life cycle. Deciphering the host factors required for the completion of the HCV 
life cycle in non-primate and non-hepatic cells is important in unravelling the biology of 
HCV, and also in providing a basis for a smaller, more suitable animal model. Therefore, 
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studies aimed at understanding host factors with respect to HCV infection and replication 
is strongly warranted. 
 
1.4 Biosynthesis of MicroRNA 
MicroRNAs are short RNA sequences that aid in post-transcriptional regulation. They are 
~22 nucleotide sequences that silence gene expression by binding to complementary 
sequences in the 3’ NTR of target mRNAs.  
The synthesis and processing of microRNAs involves 3 important steps. After the 
synthesis of the primary transcript (pri-miRNA) in the nucleus aided by the RNA 
polymerase II, the pri-miRNA undergoes a round of partial processing generating the 
precursor form, pre-miRNA. The processing into the precursor form is mediated by the 
ribonuclease III enzyme Drosha and the nuclear protein DiGeorge Syndrome Critical 
Region 8 (DGCR8) also referred to as ‘Pasha’ in invertebrates. Upon translocation to the 
cytoplasm, pre-miRNA is subjected to an additional round of processing mediated by 
ribonuclease III enzyme Dicer complex generating the mature and functional duplex 
miRNA. The mature strand consists of two segments; a ‘guide’ strand complementary to 
the target mRNA and a ‘passenger’ strand that is usually degraded. The guide strand 
complexes with Argonaute 2 protein to form the RNA-induced silencing complex (RISC). 
Once loading on the RISC complex, the miRNA is transported to the 3’NTR of the target 
mRNA where it can either cleaves it or blocks translation. 
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Figure 3: Biosynthesis of MicroRNA 
The synthesis of microRNAs requires three important steps. The synthesis of the primary transcript 
(pri-miRNA) in the nucleus is aided by the RNA polymerase II. This is then partially processed to 
form pre-miRNA by the ribonuclease III enzyme Drosha. Upon translocation to the cytoplasm by 
exportin proteins, pre-miRNA is processed by the Dicer complex to generate the mature and 
functional duplex miRNA. It is then loaded on the RISC complex, enabling it to either cleave the 
target mRNA or block translation.
87
 
 
 
1.4.1    MicroRNA-122 and HCV 
Micro RNAs are endogenous non-coding RNAs that are important transcriptional 
regulators leading to translation repression and gene silencing by degrading mRNA
88,89
. 
Originally identified in C.elegans, miRNAs have now been identified to be critical in 
process such as fatty acid metabolism, cell proliferation and apoptosis
90,91
. However, the 
exact mode of regulation remains largely elusive. MiR-122 is specifically expressed in the 
liver and is thought to be important for regulating tissue specific gene expression profiles 
92
.  
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Making up for 70% of the miRNA in the adult liver, miR-122 has been observed to play an 
important role in fatty acid metabolism and cholesterol biogenesis 
93,94
. Notably, miR-122 
has been identified as a host factor crucial for efficient replication and production of HCV 
35,95
. MicroRNA-122 interacts with two defined sites of the 5’NTR 95 which are highly 
conserved between genotypes 1 and 2a and this assembly has been shown to aid in 
regulating viral replication and translation
96
. The exact effect of miR-122 on hepatitis-C 
replication is still unclear. While some reports suggest the involvement of miR-122 in the 
accumulation of HCV RNA regulating the rate of amplification, some others suggest a 
direct role on viral translation due to increased association of the ribosome with the HCV 
RNA. In accordance to this, the binding of miR-122 to the 5’NTR is said to relieve the 
structural conformation of the viral IRES element to aid in translation. Although the exact 
mechanism remains to be elucidated, the importance of miR-122 in HCV propagation has 
been highlighted by recent therapeutic targeting of miR-122 using an antisense inhibitor as 
an approach to decrease HCV viremia 
97
. Ectopic expression of MiR-122 has also been 
shown to rescue replication levels in non-hepatic cell lines indicating its role in 
determining viral tropism
39
. Also, reduced levels of MiR-122 in patients with chronic 
Hepatitis-C are associated with poor response to IFN therapy
98
. 
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1.5 Research objectives 
The interferon system leads to the restriction of HCV replication in vitro. Consequently, 
Interferons are successfully used in therapy but not all patients achieve the desired 
sustained virological response. It is unknown whether and to what extent, IFNs contribute 
to the restriction of HCV in the mouse. 
Improvement of treatment outcome requires the analysis of HCV restriction by the 
interferon system. Therefore, there is a need to understand the IFN-dependent as well as 
independent mechanisms in detail. Additionally, in a clinical setting where patients 
develop auto-antibodies against IFNs, the individual antiviral properties exerted by the 
IRFs might be critical in determining disease outcome.  
This study, will aim at identifying the impact of IFN-dependent and IFN-independent 
mechanisms on the restriction of HCV replication. Embryonic fibroblasts and hepatocytes 
isolated from mice lacking key molecules involved in induction, reaction and amplification 
of type I IFNs will be used to determine their ability to maintain HCV replication.  
HCV is recognized by the host system which induces an interferon response against it. 
Liver biopsies of chronic HCV-infected patients exhibit increased expression levels of 
ISGs
99
. The data could be validated in experimentally infected chimpanzees
65,100
 and 
revealed that the outcome of infection could be determined by analyzing the ISGs induced 
at very early time points. To this end, a stable cell line expressing an inducible HCV 
replicon should be established that permits the detection of early host responses i.e. ISG 
expression immediately following recognition of pathogens by the cellular system.
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2. Results 
 
2.1 Chapter 1: The Role of IRFs in limiting HCV replication  
Hepatitis-C has been recognized as an emerging public health concern and the current 
treatment regimen of pegylated Interferon alpha in combination with ribavirin has proven 
only partly successful. 
Achievement of sustained virological response is variable and is dependent not only on the 
genotype of the virus but also on the infected host. Host factors such as IL28 gene 
polymorphism have been attributed to the clearance of HCV
101-104
.  Since viral clearance is 
largely inter-individual dependent even within the same genotype, it is evident that the host 
immune system has an important role in determining disease outcome. Therefore, the aim 
of this thesis was to identify the role of the interferon system in the clearance of HCV. The 
Hepatitis-C demonstrates strict species and tissue tropism. The species barrier operates at 
different levels within a cell. Firstly, HCV tropism has been attributed largely to the strict 
requirement for entry receptors 
41
 found on the cell surface of humans and chimpanzees but 
not in small rodents making infection models naturally impossible on murine backgrounds. 
Secondly, post entry; the virus can be blocked at various stages of its replication. This 
could be a result of specific cellular restriction factors that are either constitutively 
expressed or triggered upon viral invasion or due to the absence of certain complementary 
factors that aid in competent replication. 
In order to determine the function of the interferon system in limiting HCV replication, 
embryonic fibroblasts derived from mice knocked out for various effectors of the interferon 
system were used.  
 
2.1.1 Isolation and Conditional immortalization of mouse 
embryonic fibroblasts 
Embryonic fibroblasts were isolated from pregnant mice 13 days post coitus (dpc). At this 
stage of gestation, the red organs are coalesced and are easy to excise enabling isolation of 
fibroblasts. Freshly isolated mouse embryonic fibroblasts were conditionally immortalized 
using third generation self-inactivating lentiviral vector carrying the proto-oncogene large T 
antigen from Simian Virus 40 (SV40) under the control of a conditional tetracycline-
dependent promoter. Expression of the immortalization cassette depends on the presence of 
RESULTS 
25 
 
tetracycline
105
. The expression of the immortalizing cassette is carried out by the reverse 
transactivator (Tet-on system) in a bicistronic fashion. Doxycycline administration leads to 
activation of the reverse transactivator activating the positive feedback loop. Therefore, 
supplementing the cell culture media with Doxycycline, (a derivative of Tetracycline) leads 
to the activation of the Tet-dependent promoter which results in the continuous 
transcription of the immortalizing cassette. Cells transduced with lentivirus coding for the 
immortalization cassette are therefore ‘conditionally immortalized’. 
 
Large T Ag rtTAIRESpTet
R/U5RSV Δ3’LTRcppt Immortalizing cassette PRE
 
 
Figure 4 : Schematic representation of the immortalizing cassette. 
The lentiviral construct coding for immortalizing cassette containing the Large T antigen which is 
driven under the control of a tet promoter followed by the reverse transactivator connected by an 
IRES element. The entire cassette is inserted into a third generation self-inactivating lentivirus
106
. 
Adapted from: T.May et al 2007.  
 
 
This system enables the continued passage of cells in the presence of permissive conditions; 
the absence of which (without doxycycline) restricts proliferation potential enabling cells to 
attain a ‘primary-like’ phenotype 106. 
 
2.1.2 Expression of miR-122 in mouse embryonic fibroblasts 
One of the hallmarks of Hepatitis-C biology is its requirement for specific cellular factors 
essential for replication and propagation. The liver specific micro RNA, miR-122 has been 
identified as a positive enhancer of Hepatitis-C viral replication in cells of hepatic as well as 
non-hepatic origin
39,40,96
. In this study, specific miR122 sequences were cloned within 
sequences derived from mir-30
107
 downstream of a spleen foci forming virus promoter 
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(SFFV). The second cistron consisted of an encephalomyocarditis virus internal ribosomal 
entry site (EI); a green fluorescent protein (GFP); and a woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE). The miR30 sequences flanking miR-122 
enables precise cleavage of miR-122 and therefore ensures proper functioning
107
.  This third 
generation, self-inactivating lentivirus was used to transduce conditionally immortalized 
mouse embryonic fibroblasts in order to enhance HCV replication and/or translation. Cells 
positive for GFP expression were sorted by florescent activated cell sorting. 
 
  
5’LTR SFFV miR122miR30 miR30 IRES WPREeGFP
 
 
 
 
Figure 5 : The plasmid sequence coding for miR-122.  
Schematic representation of the miR-122 expression plasmid. The miR-122 cassette sequence is 
flanked by miR-30 and is driven by the Spleen Foci Forming Virus (SFFV) promoter. The second 
cistron includes an Internal Ribosomal Entry Site (IRES) upstream of an eGFP sequence. The 
woodchuck post transcriptional response element (WPRE) plays an important role in the 
enhancement of gene expression
108,109
. 
 
 
The resulting sorted GFP
+
 population was subsequently positive for miR-122 expression. 
The supplementation of miR-122 in mouse fibroblasts will aid in enhanced replication of 
HCV. 
 
2.1.3 MEFs with a competent immune signalling pathway 
restrict HCV replication 
In order to analyze the role of the innate immune pathway in the restriction of HCV 
replication, the replication of HCV in WT MEFs was studied. Since HCV is species and 
tissue tropic and displays a strict requirement for entry receptors, infection of mouse 
fibroblasts which are not natural hosts of the virus is naturally impossible. To circumvent 
this problem, a widely used surrogate - the subgenomic replicon genotype 2a; JFH-1 
(Japanese fulminant hepatitis) was utilized.   
The JFH-1 RNA requires little to no adaptation to cell culture and has been shown to 
replicate in hepatic as well as non-hepatic cells
39,110
. The JFH-1 replicon constitutes genes 
RESULTS 
27 
 
coding for both the structural as well as the non-structural proteins of the HCV genome. 
However, the subgenoimc replicon is designed to code only for the proteins expressing the 
non-structural genes along with a part of the core protein that is fused to a Firefly luciferase 
gene functioning as a reporter plasmid. In addition, since the plasmid contains a functional 
NS5B gene which codes for the viral polymerase, the subgenomic replicon is capable of 
replicating. Therefore, replication can be monitored by increasing luciferase expression. 
Additionally, a modified version of the plasmid with a deletion of three amino acids (GDD) 
in the NS5B gene coding for the polymerase enzyme (NS5BΔGDD) was utilized as a 
negative comparison to the polymerase competent stain. 
 
3’NTR5’NTR EI
NS4BNS3 4
A NS5AC F-Luc NS5B
A.
3’NTR5’NTR EI
NS4BNS3 4
A NS5AC F-Luc NS5BΔGDD
B.
 
 
 
Figure 6 : Schematic representation of HCV subgenomic replicons  
A.The HCV subgenomic replicon RNA luciferase reporter (JFH1-Luc) and B. the polymerase 
mutant NS5BΔGDD subgenomic replicon RNA luciferase reporter (JFH1-LucΔGDD). Both 
subgenomic replicons consists of the 5`NTR, the core N-terminal 12 amino-acid coding sequence 
fused in frame with the firefly luciferase gene (C F-Luc), the encephalomyocarditis virus internal 
ribosomal entry site (EI), the NS3-NS5B (the non structural proteins with specific enzymatic 
functions) coding region and the 3´NTR.  
 
 
In order to determine the replication potential of the JFH-1 subgenoimc replicon in MEFs 
with a fully competent interferon system (WT), cells were electroporated with in vitro 
transcribed RNA derived from JFH-1 and compared to the replication deficient JFH-
1ΔGDD subgenomic replicons. The transfected cells were seeded onto 12-well plates in the 
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absence of Doxycycline. Cell lysates were harvested and assayed for luciferase activity as a 
read out for replication.  
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Figure 7 : Transient replication of JFH-1 and JFH-1ΔGDD in WT MEFs 
WT MEFs expressing miR-122 were electroporated with JFH-1 or JFH-1ΔGDD RNA. Luciferase 
values were measured at 4h post electroporation (Day 0) as a read out for transfection efficiency 
and each day for the next 5 days.  
 
 
Luciferase expression at 4 hours post electroporation (Day 0) is a result of translation of 
transfected RNA and indicates transfection efficiency. However, after Day 0, luciferase 
expression measured is indicative of an NS5B enabled replicating construct. 
As shown in Figure 7, luciferase expression in WT MEFs transfected with JFH-1 or JFH-
1ΔGDD replicon was indistinguishable up to 5 days post electroporation, suggesting that 
WT MEFs were unable to maintain detectable HCV replication. 
Once HCV has replicated, the replicated strands can act as templates for translation. The 
resulting polypeptide is co- and post-translationally cleaved by host and viral proteases to 
yield individual functional proteins. Detection of HCV proteins is a direct measurement of 
replication. Therefore, the presence of HCV protein NS3 was tested by 
immunoflourescence.   
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Figure 8 : NS3 protein detection in WT MEFs 
WT MEFs stably expressing miR122 (GFP
+
) were electroporated with JFH-1 RNA or JFH-1ΔGDD 
RNA and plated on cover slips. Upon fixation, cells were stained using a primary antibody directed 
against NS3, followed by a secondary anti-mouse Cy5 conjugated antibody. Coverslips were 
mounted on Mowiol containing DAPI. 
 
 
As shown in Figure 8, NS3 protein of the HCV subgenomic replicon was not detectable by 
immunoflourescent staining on day 3 post electroporation in WT MEFs. This indicates that 
there is no detectable replication and therefore no continued translation of the HCV 
polyprotein under WT cellular conditions. 
Taken together, this suggests the presence of competent virus replication inhibition signals 
or the absence of additional cellular functions supportive of HCV replication in rodent cells. 
Additionally, supplementing cells with miR-122 did not lead to detectable HCV replication 
in WT MEFs. 
 
2.1.4 HCV replicates in IFN receptor deficient MEFs 
Since HCV is known to induce an interferon response 
111
 and replication has been shown to 
be sensitive to type I interferon, the function of the IFN receptor in limiting HCV 
replication was tested. A functional type I IFN receptor is important in inducing STAT1 
homodimerization and its subsequent binding with IRF-9 leading to the stimulation of 
interferon stimulated genes and the amplification of interferon induction. This positive 
amplification loop maintains an effective antiviral response in the cells. 
In order to elucidate the requirement of the type 1 IFN receptor in restriction of Hepatitis-C 
in murine fibroblasts, conditionally immortalized MEFs deficient in the alpha chain of the 
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type 1 Interferon receptor (IFNAR1) stably expressing miR-122 were utilized. These cells 
were transfected with the polymerase competent (JFH-1) and deficient (JFH-1ΔGDD) 
strains of the replicon. The luciferase values were determined 4 hours post electroporation 
(Day 0) as an indication of transfection efficiency and everyday for the next 5 days. 
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Figure 9 : Transient replication of JFH-1 and JFH-1ΔGDD in IFNAR-/- MEFs  
MEFs expressing miR-122 and deficient in Type 1 IFN receptor (IFNAR
-/-
) were electroporated 
with JFH-1 or JFH-1ΔGDD RNA. Luciferase values were measured at 4h post electroporation (Day 
0) as a read out for transfection efficiency and thereafter for the next 5 days.  
 
 
Figure 9 indicates that the JFH-1 strain (red line) shows detectable luciferase expression 
indicative of on-going replication whereas the luciferase expression of the NS5B deficient 
JFH-1ΔGDD (blue line) strain had dropped below detection limit. 
In order to confirm processing of the complete replicon, the presence of HCV protein NS3 
was assessed by immunoflourescence staining 3 days post transfection. 
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Figure 10 : NS3 protein detection in IFNAR
-/-
 MEFs  
IFNAR
-/-
 MEFs stably expressing miR122 (GFP
+
) were electroporated with JFH-1 RNA or JFH-
1ΔGDD RNA and plated on cover slips. Upon fixation, cells were stained using a primary antibody 
directed against NS3 (red), followed by a secondary anti-mouse Cy5 conjugated antibody. 
Coverslips were mounted on Mowiol containing DAPI. 
 
 
As shown in Figure 10, the cytoplasmic distribution of HCV protein NS3 in IFNAR
-/-
 
MEFs electroporated with JFH-1 RNA is clearly visible in contrast to the cells transfected 
with the NS5B mutant JFH-1ΔGDD confirming the presence of replicating HCV JFH-1 
RNA. 
Taken together, these data indicate that the HCV is capable of completing its replication 
cycle in mouse cells with a defective IFNAR receptor. In addition, immunoflourescence 
staining of the NS3 protein confirms complete processing of the HCV polyprotein. More 
importantly, these data indicate that HCV replication in mouse fibroblasts is sensitive to 
type I IFN; the absence of which enables continued replication.  
 
2.1.5 The role of IRF-3, STAT1 and IRF-7 in HCV 
replication 
With the role of the IFN receptor established as indispensable in limiting Hepatitis-C virus, 
the focus was to determine additional cellular factors that could limit HCV replication. 
Interferon regulator factor-3 exhibits cytoplasmic distribution in fibroblasts and is 
constitutively expressed in a latent, inactive form. This allows for immediate response to 
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viral infections eliminating the need for de novo synthesis, allowing the immediate 
production of IFN-β.  
IRF-3 functions downstream of RIG-I; an indispensible recognition receptor in the 
identification of HCV and is therefore considered critical to antiviral response. Once 
activated, IRF-3 translocates to the nucleus and aids in the transcription of IFN-β. 
To ascertain the roles of IRF-3 on the replication of HCV, MEFs deficient in IRF-3 stably 
expressing miR-122 were electroporated with RNA transcribed from JFH-1 or JFH-1ΔGDD 
subgenoimc replicons. Cells were cultured on 12- well plates and harvested at 4 hours post 
electroporation (Day 0) and every day for the following 5 days. 
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Figure 11 : Transient replication of JFH-1 and JFH-1ΔGDD in IRF-3-/- MEFs  
IRF-3
-/-
 MEFs expressing miR-122 were electroporated with JFH-1 or JFH-1ΔGDD RNA. 
Luciferase values were measured at 4h post electroporation (Day 0) as a read out for transfection 
efficiency and everyday for the next 5 days.  
 
 
In the absence of IRF-3, a sustained replication of polymerase competent HCV (red line) is 
observed from day 1 post electroporation in the transient reporter assay. This suggests that 
the RIG-I induced IRF-3 dependent pathway is pivotal in restricting HCV replication. 
Taken together, these data indicate that in addition to the presence of the type I IFN 
receptor, IRF-3 is an important factor in limiting HCV replication. 
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STAT1, a member of the (Signal Transducers and Activators of Transcription) family is an 
indispensable transcription factor which can dimerize with STAT3 or with itself to bind the 
GAS (Interferon-Gamma Activated Sequence) promoter element or heterodimerize with 
STAT2 to bind the ISRE (Interferon Stimulated Response Element) promoter element
112
. 
Further, given the importance of STAT1 in continued IFN signalling and induction of IFN-
αs in establishing an antiviral response, it is not surprising that HCV has evolved to actively 
counteract this signalling pathway. HCV proteins NS5A 
113
 and core
3,111
 have been shown 
to interact with STAT1, inhibiting its phosphorylation and degrading it using a proteasome-
dependent mechanism.  
In order to verify the role of STAT1 proteins in HCV replication inhibition, STAT1
-/-
 MEFs 
stably expressing mir-122 were transfected with JFH-1 or JFH-1ΔGDD in vitro transcribed 
RNA. 
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Figure 12 : Transient replication of JFH-1 and JFH-1ΔGDD in STAT1-/- MEFs 
STAT1
-/-
 MEFs expressing miR-122 were electroporated with JFH-1 or JFH-1ΔGDD RNA. 
Luciferase values were measured at 4h post electroporation (Day 0) as a read out for transfection 
efficiency and everyday for the next 5 days.  
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The data shown above indicates that JFH-1 strain was capable of replication whereas the 
JFH-1ΔGDD was not. The maximum replication potential was observed at day 2 post 
electroporation following which the luciferase expression dropped consistently but did not 
reach undetectable levels. This indicates a functional role of STAT1 in limiting HCV 
replication. These data indicate that the STAT1 pathway is mandatory in limiting HCV 
replication.  
Unlike IRF-3, IRF-7 is induced in response to infection during the amplification process of 
the IFN loop and is therefore not considered an early response gene. Additionally, IRF-3 
and IRF-7 are capable of binding to each other to form heterodimers that translocate to the 
nucleus to induce differential genes. 
Similarly, IRF-7
-/-
 MEFs were electroporated with JFH-1 and JFH-1ΔGDD and the 
luciferase expression was monitored from cells lysates harvested at 4 hours (D0) post 
electroporation and every day for the next  days. 
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Figure 13 : Transient replication of JFH-1 and JFH-1ΔGDD in IRF-7-/- MEFs 
IRF-7
-/-
 MEFs expressing miR-122 were electroporated with JFH-1 or JFH-1ΔGDD RNA. 
Luciferase values were measured at 4h post electroporation (Day 0) as a read out for transfection 
efficiency and everyday for the next 5 days.  
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The data show no detectable luciferase expression in both JFH-1 and the JFH-1ΔGDD 
replicons after Day 0. This indicates that the expression levels observed at day 0 were 
derived from the transfected RNA and that the expression could not be maintained in the 
following days. This suggests that the JFH-1 replicon was not able to replicate in MEFs in 
the absence of IRF-7. 
To confirm these findings, immunoflourescent staining was performed on electroporated 
cells 3 days post transfection to determine if the viral NS3 protein was present. 
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Figure 14 : NS3 protein detection in IRF-7
-/-
 MEFs  
IRF-7
-/-
 MEFs stably expressing miR122 (GFP
+
) were electroporated with JFH-1 RNA  and plated 
on cover slips. Upon fixation, cells were stained using a primary antibody directed against NS3, 
followed by a secondary anti-mouse Cy5 conjugated antibody. Coverslips were mounted on 
Mowiol containing DAPI. 
 
 
In contrast to IRF-3 deficient MEFs, no luciferase expression of the HCV replicon was 
observed in IRF-7
-/-
 (Figure 13) cells after the initial 4 hour peak. This indicates that the 
HCV subgenomic replicon is not able to replicate. In line with this observation, no NS3 
protein was detectable by immunoflourescence. These data indicate that IRF-7 is not 
essential to restrict HCV replication in MEFs.  
Taken together, these results suggest the importance of IRF-3 and the type I interferon 
receptor in limiting HCV replication in mouse fibroblasts. In contrast, although interferon 
regulatory factor-7 is required for the amplification of the immune response, it does not 
play a dominant role in limiting HCV replication.  
 
2.1.6 The role of IRF-5 in HCV replication 
The functional relevance of IRF-5, in comparison to the other IRFs is largely unclear. 
Although a lot is known about the role of IRF-5 with regard to autoimmune disorders, the 
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exact function of IRF-5 as an antiviral protein is still elusive. Infection with VSV and NDV 
activate IRF-5 and over-expression of IRF-5 during viral infections has been reported to 
induce distinct IFNα 114. The capacity of IRF-5 to heterodimerize with IRF-3 and induce 
distinct sets of genes might indicate its ability to tailor cellular responses appropriate to 
specific viruses. In order to ascertain the role of IRF-5 in inhibiting HCV replication, IRF-5
-
/-
 mouse fibroblasts stably expressing miR-122 were transfected with RNA transcribed from 
JFH-1 and JFH-1ΔGDD subgenomic replicons. Luciferase expression was measured at 4 
hours post electroporation (Day 0) and everyday for the next 5 days.  
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Figure 15 : Transient replication of JFH-1 and JFH-1ΔGDD in IRF-5-/- MEFs 
IRF-5
-/-
 MEFs expressing miR-122 were electroporated with JFH-1 or JFH-1ΔGDD RNA. 
Luciferase values were measured at 4h post electroporation (Day 0) as a read out for transfection 
efficiency and everyday for the next 5 days.  
 
 
As shown in Figure 15, the luciferase expression of the JFH-1 was comparable to that of 
the polymerase deficient strain suggesting its inability to replicate. This indicates that the 
absence of IRF-5 in mouse fibroblasts does not rescue HCV replication and that IRF-5 has 
no dominant role in limiting HCV replication. 
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2.1.7 The role of IRF-1 in HCV replication 
The role of IRF-1 in treatment response in patients with HCV has been reported
115,116
. 
Specific SNP (-300AA) in the promoter regions of IRF-1 have been associated with better 
treatment outcome
115
. In order to elucidate the function of IRF-1 in the replication of HCV, 
embryonic fibroblasts derived from mice knocked-out for IRF-1 stably expressing miR-122 
were used. RNA transcribed from polymerase competent or polymerase deficient JFH-1 
strains were electroporated into IRF-1 knock-out MEFs. Luciferase expression from the 
subgenomic replicon was measured at 4 hours (Day 0) post electroporation indicative of 
electroporation efficiency and up to day 5 to detect replication.  
Days post electroporation 
0 1 2 3 4 5
R
L
U
 (
lo
g
 1
0
)
2
3
4
5
JFH-1
JFH-1 GDD
 
 
Figure 16 : Transient replication of JFH-1 and JFH-1ΔGDD in IRF-1-/- MEFs 
IRF-1
-/-
 MEFs expressing miR-122 were electroporated with JFH-1 or JFH-1ΔGDD RNA. 
Luciferase values were measured at 4h post electroporation (Day 0) as a read out for transfection 
efficiency and everyday for the next 5 days.  
 
 
As depicted above, the luciferase expression of JFH-1 were comparable to that of JFH-
1ΔGDD. Replication of HCV in the absence of IRF-1 was not observed suggesting that 
IRF-1 was not important in restricting HCV replication.  
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Figure 17 : NS3 protein detection in IRF-1
-/-
 MEFs  
IRF-1
-/-
 MEFs stably expressing miR122 (GFP
+
) were electroporated with JFH-1 RNA and plated 
on cover slips. Upon fixation, cells were stained using a primary antibody directed against NS3, 
followed by a secondary anti-mouse Cy5 conjugated antibody. Coverslips were mounted on 
Mowiol containing DAPI. 
 
 
Immunoflourescence staining of the NS3 viral protein did not yield any signal suggesting 
that the IRF-1
-/-
 MEFs could not support viral replication and subsequent translation. This 
suggests that IRF-1 is not directly involved in the clearance or restriction of HCV. 
 
2.1.8 PKR in HCV replication 
PKR (Protein kinase R) belongs to a family of kinases that regulate cellular translation in 
response to environmental stress. In steady state, PKR is an inactive monomer. It is a serine 
kinase that is autophosphorylated following binding with dsRNA. Thus activated, 
phosphorylated PKR further phosphorylates eukaryotic initiation factor eIF-2 inhibiting 
translation. PKR also phosphorylates IκB, the inhibitory subunit of NFκB.  
PKR has been reported as a binding partner of STAT1, where this physical interaction has 
been described to modulate the transcriptional activity of STAT1 
48
. Studies in PKR-
deficient fibroblasts have confirmed that PKR is involved in protection against several virus 
infections, including HIV-1 
80
, HCV 
87
 , and hepatitis D virus 
112
. 
In order to ascertain the relevance of PKR in HCV replication, MEFs knocked out for PKR 
and expressing miR-122 were transfected with RNA from JFH-1 or JFH-1ΔGDD. Cells 
were cultured on 12-well plates and cell lysates were harvested at 4 hours post 
electroporation (Day 0) and everyday for the following 5 days. 
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Figure 18 : Transient replication of JFH-1 and JFH-1ΔGDD in PKR-/- MEFs 
PKR
-/-
 MEFs expressing miR-122 were electroporated with JFH-1 or JFH-1ΔGDD RNA. 
Luciferase values were measured at 4h post electroporation (Day 0) as a read out for transfection 
efficiency and everyday for the next 5 days.  
 
 
As shown above, luciferase expression dropped down until day 2 post electroporation after 
which an increase in replication signals was observed. This suggests a possible inhibitory 
role of PKR in HCV replication. 
 
2.1.9 MAVS in HCV replication 
The Mitochondrial antiviral-signalling protein (MAVS) also referred to as VISA, Cardif or 
IPS-1 is an important mediator of the RIG-I dependent IFN pathway. Following RIG-I 
activation, MAVS proteins on the mitochondrial membrane interact with RIG-I through 
CARD-CARD interactions. This phosphorylates and activates cytosolic IRF-3 and NFκB, 
which translocates to the nucleus. This leads to the induction of IFN-β and the subsequent 
ISGs.  
Since MAVS is mandatory to the RIG-I mediated response, HCV has evolved its NS3/4A 
protease to cleave the MAVS protein
1
. 
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In order to understand the role of MAVS in HCV replication, MAVS
-/-
 MEFs expressing 
miR-122 were electroporated with RNA transcribed from JFH-1 or JFH-1ΔGDD. Cells 
were cultured on 12-well plates and cell lysates were harvested 4 hours post electroporation 
(Day 0) and everyday for the next 5 days. 
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Figure 19 : Transient replication of JFH-1 and JFH-1ΔGDD in MAVS-/- MEFs 
MAVS
-/-
 MEFs expressing miR-122 were electroporated with JFH-1 or JFH-1ΔGDD RNA. 
Luciferase values were measured at 4h post electroporation (Day 0) as a read out for transfection 
efficiency and everyday for the next 5 days.  
 
 
As shown above, no significant increase in luciferase expression derived from JFH-I RNA 
was observed in these cells in comparison to the polymerase mutant. This indicates that 
although MAVS protein in crucial in mediating a RIG-I dependent response, it is not the 
only pathway operating against HCV replication. The TLR-3 mediated TRIF pathway that 
activates cytosolic IRF-3 could be responsible in mediating an antiviral cellular state. 
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2.2 Chapter 2: Interferon independent pathways limiting 
HCV replication. 
 
2.2.1   HCV replication induces interferon secretion in cells  
The interferons are critical mediators of an antiviral response. The type I IFNs are the most 
frequently induced cytokines during an infection. These pleiotropic cytokines act in 
autocrine and paracrine ways to activate host cell antiviral responses and alert the 
surrounding cells of a viral invasion. The HCV RNA has specific structures coded by its 
genome that act as potent interferon inducers
117. The poly (U/UC) tract at the 3’terminus 
and the 5’ppp are reported to be the major pathogen signatures recognized by RIG-I and the 
double stranded intermediates formed as a result of replication are recognized by TLR3. 
Within a cell, these molecular signatures are recognized by pattern recognition receptors 
that induce an interferon response, thereby establishing an antiviral state
63,117-120
.  
However, the evolutionarily evolved HCV has developed mechanisms to successfully evade 
these immune cascades. The HCV NS3/4A protein cleaves adaptors TRIF, MAVS and also 
successfully counteracts the STAT1 signalling mechanism. Therefore, upon HCV infection, 
interferon induction is severely compromised especially in cell culture and is difficult to 
detect. It was therefore important to analyze if fibroblasts transfected with the HCV 
replicon could be recognized by the PRRs and induce an interferon response. Additionally, 
since type I and type III interferons are capable of limiting HCV, the type of interferon 
produced by the fibroblasts was determined. 
 
2.2.2    Replication of sub-genomic HCV replicon induces IFN 
secretion 
HCV is reported to induce IFN in patients. Also, it is known that HCV is susceptible to IFN 
response. Therefore, it was important to determine if IFN was induced by HCV and if the 
mouse fibroblasts secreted IFN upon transfection. To this end, bioactive Interferon in the 
supernatant was quantified by luciferase expression in intestinal epithelial cell lines 
expressing luciferase under the control of the IFN-induced Mx2 promoter
121
. The IECs 
were incubated with supernatant harvested from MEFs electroporated with JFH-1 and the 
JFH-1ΔGDD strains. Reporter cell lines were incubated for 24 hours with supernatant 
RESULTS 
42 
 
collected at several time points (Day 0, D1 and D2) post electroporation, and luciferase 
expression was measured. 
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Figure 20 : Detection of Interferon secretion in HCV replicon transfected MEFs 
Intestinal epithelial cells derived from an IFN reporter mouse carrying an Mx2 promoter-controlled 
luciferase construct 
121
 were stimulated with supernatants of the cells. Epithelial cells were 
incubated for 24 hours with supernatant from MEFs (WT, IFNAR
-/-
, IRF-7
-/-
, IRF-1
-/-
 and IRF-5
-/-
) 
electroporated with JFH-1 and the JFH-1ΔGDD for 4 hours (Day 0), day1 and day 2. The luciferase 
values were measured and quantified in U/ml. 
 
 
As shown in Figure 20, upon transfection, the JFH-1 replicon induced IFN levels in all 
electroporated MEFs. The highest levels of IFN secreted was measured in WT MEFs 
(30U/ml) while IFNAR
-/-
, IRF-7
-/-
, IRF-1
-/-
 and IRF-5
-/- 
showed less but detectable levels of 
IFN.
  
However, the JFH-1ΔGDD induced detectable IFN levels in WT and IRF-1-/- MEFs. 
This could be explained as a result of cellular recognition of molecular patterns of 
transfected RNA. 
Taken together, these data indicate that the JFH-1 and the JFH-1ΔGDD encode pathogen 
signatures that are recognized by the cellular interferon machinery. However, the JFH-1 
strain, capable of replication induces higher levels of interferon in comparison to the NS5B-
deficient strain. This can be explained by the double stranded intermediates that the positive 
sense single stranded HCV RNA forms during the process of replication. These 
intermediates act as inducers of the TLR3 signalling pathway
122
. 
Taken together, these data indicate that both JFH-1 and JFH-ΔGDD HCV RNA can induce 
a detectable interferon response. This suggests that the HCV replicon encodes in itself 
molecular signatures that can be detected by the host immune system. Additionally, 
replication competent HCV induced IFN secretion much higher than the polymerase 
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deficient strain suggesting that although HCV replicon specific structures could induce an 
interferon response, replicating HCV replicons induced much higher levels of interferon.  
 
2.2.3 Mouse fibroblasts secrete type I interferon 
Both, type I IFN and type III IFN are shown to induce antiviral responses restricting HCV 
replication
101,102
. Bioactive Interferon in the supernatant was quantified by luciferase 
expression in intestinal epithelial cell lines expressing luciferase under the control of the 
IFN-induced Mx2 promoter
121
. Intestinal epithelial cells are sensitive to Type I and III IFN 
as intestinal epithelia posses both the type I and the type III IFN receptors. Supernatant was 
harvested from electroporated MEFs that were cultured in the presence or absence of 
neutralizing antibodies against type I interferon at 4 hours (Day 0), day 1 and day 2 post 
electroporation. Intestinal epithelial cells were incubated with the supernatant for 24 hours 
and the luciferase values were measured.  
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Figure 21 : MEFs secrete Type I Interferon 
For the IFN bioassays, supernatants of WT, IFNAR
-/-
 , IRF-7
-/-
, IRF-5
-/-
 and IRF-1
-/-
 cells 
electroporated with RNA from JFH1 were harvested 4h (0) or 1 and 2 days post electroporation. 
Reporter intestinal epithelial cells derived from an IFN reporter mouse carrying an Mx2 promoter-
controlled luciferase construct 
121
 were stimulated with supernatants of the cells. Luciferase activity 
was determined after 24h. To determine the IFN species, cells were incubated with 2 µg/ml of IFNα 
(4EA1) and IFN-β (7FD3) antibodies neutralizing 500U of IFN. IFN concentrations were obtained 
by administering serial dilutions of IFN-β. The luciferase values were measured and quantified in 
U/ml. 
The experiment demonstrates that replicating JFH-1 is capable of inducing detectable levels 
of interferon in all transfected MEFs as measured by the Mx2 luciferase reporter assay. 
Additionally, when type I IFN was neutralized, luciferase expression was completely 
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abolished suggesting that Mx2 induction was solely dependent on the type I IFN response 
and not the type III IFNs. This indicates that mouse fibroblasts secrete type I IFN following 
HCV replication. 
 
2.2.4 Blocking the paracrine IFN response does not rescue 
HCV replication in WT MEFs 
Interferon secreted by a cell upon viral encounter is taken up by specific IFN receptors to 
aid amplification of this response. In addition to the infected cell, the paracrine mode of 
IFN signalling ensures the establishment of an antiviral state in neighbouring cells. Since 
the secretion of interferon by the electroporated cells has been established, their plausible 
influence on HCV replication was analyzed. WT MEFs electroporated with polymerase 
competent or deficient JFH-1 RNA were cultured on 12-well plates in the presence of 
absence of neutralizing antibodies (2μg/ml) against Type I IFN. Cells were harvested at 4 
hours post electroporation (Day 0) to determine transfection efficiency and everyday for the 
next 5 days.  
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Figure 22 : Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in WT 
MEFs 
WT MEFs were electroporated with JFH-1 RNA. The electroporated cells were cultured on 12-well 
plates without (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α (4EA1) 
and IFN-β (7FD3). 
RESULTS 
45 
 
As shown in Figure 22, there was no detectable expression of luciferase expression of JFH-
1 replicon. Expression levels were comparable to the JFH-1ΔGDD replicon. Treatment of 
the cells with neutralizing antibodies against type I IFNs had no influence on the replication 
of the HCV subgenomic replicon. This suggests that neutralization of secreted IFN could 
not rescue HCV replication in WT mouse fibroblasts indicating that although HCV 
restriction depends on type I IFN receptor Figure 9, the presence of more restriction factors 
than type I interferon. 
 
2.2.5 Neutralizing type I IFN response does not enhance HCV 
replication in IFNAR
-/-
 MEFs 
Although MEFs with a lesion in the IFN receptor are not responsive to IFNs, they are 
capable of producing IFN in response to a pathogen attack. This response is however 
limited due to the defect in the continued amplification of the initial response. Therefore, 
cells and animals deficient in the IFN receptor have been shown to be extremely susceptible 
to viral infections. 
To determine if replication could be enhanced in the absence of a positive IFN 
amplification loop, cells were electroporated with RNA transcribed from JFH-1 replicon 
and cultured in the presence or absence of  neutralizing antibodies against IFN-α and IFN-β. 
The cells were harvested at 4 hours post transfection (Day 0) and everyday for the next 5 
days. 
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Figure 23 : Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in 
IFNAR1
-/-
 MEFs 
IFNAR1
-/-
 MEFs were electroporated with JFH-1 RNA. The electroporated cells were cultured on 
12-well plates without (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α 
(4EA1) and IFN-β (7FD3). 
 
 
Although IFN secreted from these cells could be detected, depletion of IFN-α and IFN-β by 
neutralizing antibodies did not further increase HCV replication. 
Taken together, this indicates that in addition to restriction factors operating at the level 
prior to IFN induction, the positive amplification of IFN via the IFN receptor is 
indispensible to HCV restriction in mouse fibroblasts and as expected, replication is not 
enhanced further by neutralizing secreted IFNs. 
 
2.2.6 IRF-3 dependent HCV restriction 
The role of another interferon regulatory factor, IRF-3 has been shown to be important in 
limiting HCV in mouse fibroblasts. IRF-3 has been shown to induce antiviral ISGs directly 
and is responsible for inducing early type I interferon. Although HCV was shown to 
replicate in the absence of IRF-3, it was tested if the additional deletion in the IFN 
amplification loop could enhance HCV replication. To this end, IRF-3
-/-  
MEFs were 
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electroporated with RNA transcribed from JFH-1 replicon and cultured in the presence or 
absence of neutralizing antibodies against IFN-α and β. Cells were harvested at 4 hours post 
electroporation (Day 0)  to determine transfection efficiency and everyday for  the next 5 
days. 
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Figure 24 :  Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in 
IRF-3
-/-
 MEFs  
IRF-3
-/-
 MEFs were electroporated with JFH-1 RNA. The electroporated cells were cultured on 12-
well plates without (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α 
(4EA1) and IFN-β (7FD3). 
 
As depicted above, in the IRF-3
-/-
 MEFs, the added lesion in the IFN amplification loop did 
not further enhance HCV replication in comparison to when only IRF-3 was deleted.  This 
indicates that IRF-3 alone is sufficient to restrict HCV replication, may be because no IFN 
is induced in the absence of IRF-3. 
 
2.2.7 STAT1 induced restriction of HCV replication 
STAT1 is an important transcription factor that induces downstream interferon stimulated 
genes in response type I, II and type III interferon. The STAT1 proteins are crucial in 
antiviral defence and hence it is not surprising that viruses have evolved strategies to evade 
the STAT1 response. The core protein of HCV has been shown to associate with STAT1 
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and induce degradation in a proteasome-dependent manner. Additionally, the HCV NS5A 
has been observed to inhibit STAT1 phosphorylation, suppressing nuclear translocation and 
the ensuing immune response. 
In order to validate the IFN-independent role of STAT1, mouse fibroblasts deficient in 
STAT1 were utilized to study HCV replication.  
To this end, immortalized STAT1
-/-
 MEFs were electroporated with RNA transcribed from 
JFH-1 replicon and cultured in the presence or absence of neutralizing antibodies against 
IFN-α and β. Cells were harvested at 4 hours post electroporation (Day 0)  to determine 
transfection efficiency and everyday for  the next 5 days. 
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Figure 25 : Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in 
STAT1
-/-
 MEFs 
STAT1
-/-
 MEFs were electroporated with JFH-1 RNA. The electroporated cells were cultured on 
12-well plates without (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α 
(4EA1) and IFN-β (7FD3) 
 
 
As shown above, no additional luciferase expression was observed following neutralization 
of the type I interferon response.  
STAT proteins complex with IRF-9 to form the ISGF3 complex that translocates to the 
nucleus and results in their binding to the consensus elements on promoters of interferon 
stimulated genes. This suggests that although the STAT1 is required for limiting HCV 
RESULTS 
49 
 
replication by amplifying the IFN response, it is dependent on the positive amplification of 
the type I IFN and the induction of ISGs.  
 
2.2.8 IFN independent pathways for limiting HCV replication  
The interferon system has evolved to protect cells from a viral attack. Therefore, in the 
context of a viral infection, the IFN system is particularly indispensible. Although the 
regulators of the interferon system (the IRFs) are largely homologous and redundant in their 
activities and pivotal in protecting an infected cell, it is believed that the interferons evolved 
to protect uninfected neighbouring cells as well. This suggests that in addition to IFN driven 
antiviral responses, IRF mediated antiviral pathways may play a role in viral defence
5,123
. 
Since no rescue of HCV was observed in WT MEFs upon disabling the IFN response, we 
hypothesized the presence of an additional factor prior to the IFN amplification loop aiding 
in limiting HCV replication.  
In order to test the impact of these IFN-independent antiviral pathways, MEFs, individually 
deficient in interferon regulatory factors were tested for their ability to support HCV 
replication in the combined absence of the IFN amplification loop.  
IRF-5 has been studied in relation with autoimmune diseases and its role in antiviral 
immunity is emerging. When present in the cell, it is found in its latent form which gets 
activated upon infection and translocates to the nucleus. Although morphine 
124
 and 
methamphetamine 
125
 have shown to suppress the expression of p38 and IRF-5 respectively 
increasing HCV replication in hepatocytes, the role of IRF-5 in limiting HCV is still largely 
elusive.  
In order to ascertain the role of IRF-5 in the absence of a functional interferon response, 
MEFs deficient in IRF-5 were utilized to analyze the replication of HCV. 
To this end, IRF-5
-/-
 MEFs were electroporated with RNA transcribed from JFH-1 replicon 
and cultured in the presence or absence of neutralizing antibodies against IFN-α and β. 
Cells were harvested at 4 hours post electroporation (Day 0)  to determine transfection 
efficiency and everyday for  the next 5 days. 
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Figure 26 : Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in 
IRF-5
-/-
 MEFs  
IRF-5
-/-
 MEFs were electroporated with JFH-1 RNA. The electroporated cells were cultured on 12-
well plates without (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α 
(4EA1) and IFN-β (7FD3).  
 
The data shown above indicate that the absence of IRF-5 (red line) alone is not sufficient to 
sustain HCV replication. However, in the added deletion of the IFN response, HCV 
replication can be observed. 
The significant increase in HCV replication compared to when only IRF-5 was deleted 
suggests the presence of additional antiviral mechanisms dependent on IRF-5 but 
independent of type I interferons. 
IRF-7 is involved in the amplification of interferon responses and is also induced by 
interferon. Although HCV has been shown to functionally inhibit IRF-7 by effectively 
blocking nuclear translocation 
126
 in hepatocytes, it was observed to be dispensable for 
limiting HCV replication in mouse fibroblasts. In order to ascertain the IFN- independent 
role of IRF-7 in limiting HCV replication, mouse fibroblasts isolated from IRF-7
-/- 
mice 
were studied for HCV replication. 
To this end, IRF-7
-/-
 MEFs were electroporated with RNA transcribed from JFH-1 replicon 
and cultured in the presence or absence of neutralizing antibodies against IFN-α and β. 
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Cells were harvested at 4 hours post electroporation (Day 0) to determine transfection 
efficiency and everyday for  the next 5 days. 
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Figure 27 :  Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in 
IRF-7
-/-
 MEFs.  
IRF-7
-/-
 MEFs were electroporated with JFH-1 RNA. The electroporated cells were cultured on 12-
well plates without (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α 
(4EA1) and IFN-β (7FD3) 
 
 
As shown above, the JFH-1 replicon could not replicate in the absence of IRF-7. However, 
in the combined absence of IRF-7 and the IFN signalling pathway a rescue in HCV 
replication could be observed. This suggests a plausible function of IRF-7 in limiting HCV 
replication. 
Similarly, the role of IRF-1 in HCV viral clearance and response to treatment has been 
elucidated in patient cohorts
115
.  Therefore, in order to elucidate the IFN-independent 
antiviral function of IRF-1, HCV replication was studied in IRF-1
-/-
 MEFs. 
To this end, IRF-1
-/-
 MEFs were electroporated with RNA transcribed from JFH-1. The 
cells were cultured on 12-well plates in the presence or absence of neutralizing antibodies 
against IFN-α and β. Cells were harvested at 4 hours post electroporation (Day 0) to 
determine transfection efficiency and everyday for  the next 5 days. 
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Figure 28 :  Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in 
IRF-1
-/-
 MEFs  
IRF-1
-/-
 MEFs were electroporated with JFH-1 RNA. The electroporated cells were cultured on 12-
well plates without (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α 
(4EA1) and IFN-β (7FD3).  
 
As shown above, the data indicate an increased replication of the JFH-1 replicon in the 
absence of IRF-1 and IFN amplification when compared to only in the absence of IRF-1 
 
In comparison to the WT MEFs with a fully able innate immune system, where no 
replication of HCV was observed upon blocking the paracrine response, HCV was seen to 
replicate in the additional absence of IRF-1. This suggests the potential role of IRF-1 in 
limiting HCV replication in the absence of a type I IFN response.  
 
Protein kinase R (PKR) has been reported to be pivotal in antiviral defence. Following 
binding to dsRNA, PKR dimerizes and undergoes autophosphorylation. Thus activated, 
PKR phosphorylates eIF2A suppressing the translation machinery. In order to circumvent 
the lack of the host translational machinery, HCV has developed a functional IRES element. 
The IRES element aids in ribosome-mediated translation of the viral proteins. 
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In order to determine the role of PKR in an IFN-independent setting, PKR
-/-
 MEFs were 
assayed for HCV replication.  
To this end, PKR
-/-
 MEFs were electroporated with RNA transcribed from JFH-1 replicon 
and cultured in the presence or absence of neutralizing antibodies against IFN-α and β. 
Cells were harvested at 4 hours post electroporation (Day 0)  to determine transfection 
efficiency and everyday for  the next 5 days. 
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Figure 29 : Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in 
PKR
-/-
 MEFs  
PKR
-/-
 MEFs were electroporated with JFH-1 RNA. The electroporated cells were cultured on 12-
well plates without (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α 
(4EA1) and IFN-β (7FD3).  
 
 
As depicted above, although slight luciferase expression could be determined in the absence 
of PKR, the combined absence of PKR and the type I IFN amplification loop permitted 
enhanced replication. This suggests that PKR functions in inhibiting HCV replication in a 
manner independent of the type I IFN response. Because PKR expression is dependent of 
type I IFN, depletion of constitutive low levels of type I IFN could reduce PKR expression 
and therefore PKR dependent restriction of HCV replication. 
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2.3 Chapter 3: Generation of an inducible HCV cell line 
 
The understanding of the pathogenesis and persistence of the Hepatitis-C virus has been 
severely hindered due to the lack of suitable cell culture systems. Most available cell 
systems are based on human hepatoma cell lines such as Huh7 and its derivatives. The 
interferon and the ensuing interferon stimulated genes (ISGs) are pivotal in limiting HCV. 
Data generated from infection studies on chimpanzees reveal differential outcomes based 
on the time of induction of ISGs following an infection. It has been observed that 
immediate to high induction of ISGs upon infection results in acute infection which is later 
cleared, whereas a decreased or delayed ISG response to infection is associated with 
chronicity in chimpanzees experimentally infected with HCV
100
.  
Transient transfection of cells in culture is limited by the number of cells ‘hit’, ie: not all 
cells are positively transfected leading to an ‘asynchronic’ response. In order to circumvent 
this varied response, a plasmid coding for an HCV subgenomic replicon JFH-1 was cloned 
downstream of an inducible Tet promoter. An inducible promoter allows for the expression 
of the cassette under specific permissive conditions.  
The advantage of a Tet dependent construct coding for the JFH-1 replicon is that it can be 
induced by supplementing cell culture media with a Tetracycline derivative (Doxycycline). 
Co-transfection of a construct containing a KRAB repressor allows for strict expression of 
the gene of interest only under permissive conditions thereby avoiding possible leaky 
expression. The expression of the cassette is based on the ‘Tet-off’ system wherein the gene 
of interest is maintained at a ‘switched-off’ mode in the presence of Doxycycline.  
Apart from the advantage of inducibility in gene expression, clonal expansion of cells 
stably expressing the plasmid results in a pool of cells responding in a synchronous manner. 
Importantly, this system permits the identification of interferon responses immediately after 
encountering the viral genome. This is important as the first set of ISGs induced by the 
activated IRF-3 is relatively less and difficult to detect especially if only a fraction of the 
cell population is transfected. A synchronic cellular response against the viral genome 
permits detection of early immune responses. 
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2.3.1 Establishment of Huh7.5 cells expressing a stable Tet 
inducible HCV subgenoimc replicon 
Huh7.5 cells are human hepatoma cells derived from the Huh7 cell line. Hepatoma cells 
exhibit downregulated TLR3 expression
2
. In addition to deficient TLR3, these cells have an 
additional lesion in the RIG-I making Huh7.5
118
 cells permissive to HCV replication.  
The aim was to generate Huh7.5 cells stably expressing a plasmid coding for a Tet 
inducible HCV replicon to establish a tool which allows the identification of early cellular 
ISG response upon HCV replication. 
Huh7.5 cells stably expressing inducible JFH-1 and the NS5B-deficient JFH-1ΔGDD 
subgenoimc replicons were generated. To this end, the Huh7.5 cells were transfected with a 
plasmid containing the JFH-1 or the JFH-1ΔGDD subgenoimc replicon cloned downstream 
of a Tet promoter (Figure 30 A), and co-transfected with a lentiviral vector containing the 
transactivator including the rKRAB sequence. The KRAB repressor under the constitutive 
PGK promoter ensures tight expression whereas the presence of a mutated nerve growth 
factor acts as a surface marker enabling detection of transfected cells by 
immunoflourescence or microscopy. The PGK driven KRAB repressor is connected to the 
transactivator through an EMCV-IRES sequence.  
3’NTR5’NTR EI
NS4BNS3 4A NS5AC F-Luc NS5B
A.
B.
Tet
tTAEIrtKRABPGKCMVΔNGFR
 
Figure 30: Schematic representation of A. The tet inducible HCV plasmid and B. the lentiviral 
plasmid coding for the transactivator. 
 
A. The Tet promoter is introduced in front of the JFH-1 subgenoimc replicon. B. The third 
generation self-inactivating lentiviral plasmid expressing the KRAB repressor connected to a 
transactivator by an EMCV-IRES (EI) transcriptionally driven by the PGK promoter. Additionally, 
a mutated nerve growth factor receptor is driven by the CMV promoter. 
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2.3.2 The Tet dependent plasmids show inducible expression  
In order to test the inducibility of the plasmid containing the tetracycline-inducible HCV 
subgenomic replicon, Huh7.5 cells were transiently transfected with the inducible replicons 
(JFH-1-prom3 or JFH-1ΔGDD-prom3) and the plasmid containing the transactivator (Lenti 
tTA). Transfection efficiency was normalized by co-transfection of a Renilla Luciferase 
plasmid. 
Upon transfection, the cells were maintained in the absence of Doxycycline for three days 
in order to aid Tet-dependent transcription. Following this, the cells treated with or without 
Doxycycline (2μg/ml) and the luciferase values were recorded daily for a period of 5 days. 
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Figure 31: Inducible expression of the HCV replicons. 
The Tet inducible plasmids JFH-1 and IFH-1ΔGDD were transfected in the presence of a lentiviral 
plasmid coding for the transactivator along with the reporter plasmid pMdicR-luc. Upon 
transfection, the cells were maintained in the absence of Doxycycline for three days. Following this, 
the cells treated with or without Doxycycline (2μg/ml) and the luciferase values were recorded 
everyday for a period of 5 days. Luciferase values were measured and normalized to the Renilla 
luciferase values. 
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Luciferase values were measured in cells incubated in the presence or absence of Dox each 
day for up to 5 days. The normalized values revealed increasing levels of luciferase 
expression in the absence of Doxycycline with time. This is a result of continued 
transcription in the absence of Doxycycline (red and dark blue bars). Additionally, the 
slight increase in luciferase expression levels observed in the JFH-1 replicon (red bars) in 
comparison to the JFH-1ΔGDD (dark blue bars) in the absence of Doxycycline could be a 
result of NS5B enabled replication of the JFH-1 strain.  
In contrast, when cells are cultured in the presence of Dox, the Tet-induced transcription is 
switched off and no luciferase expression is observed in the JFH-1 (light blue bars) and the 
JFH-1ΔGDD constructs (yellow bars). 
Taken together, these data suggest that the absence of doxycycline induces Pol II dependent 
transcription in both the inducible JFH-1 as well as the JFH-1ΔGDD constructs. 
Additionally, the slight increase in luciferase expression observed in the JFH-1 and the 
JFH-1ΔGDD constructs could be due to NS5B polymerase dependent replication. 
Since Figure 31 establishes that transcription of these constructs could be regulated, the 
increase in luciferase expression of the JFH-1 in comparison to JFH-1ΔGDD was attributed 
to plausible replication of the JFH-1 replicon. To this end, the plasmids were tested for their 
capacity to replicate following Dox induced transcription. 
 
2.3.3 The plasmids exhibit the potential to replicate  
Transient induction assays of JFH-1-prom3 showed a slight increase in luciferase 
expression in comparison to the JFH-1ΔGDD-prom3 construct. This trend was 
hypothesized to be due to the added ability of the JFH-1-prom3 to replicate aided by the 
viral polymerase NS5B. The three amino acid mutation in the JFH-1ΔGDD disrupts viral 
polymerase inhibiting the construct from replicating. 
In order to verify if the polymerase competent strain (JFH-1-prom3) could initiate and 
maintain replication after Tet induction, a replication assay in the presence of NS5B 
polymerase inhibitor 2-CMA was performed. To this end, Huh7.5 cells transiently 
transfected with JFH-1-prom3 (POL+) or JFH-1ΔGDD-prom3 was co-transfected with lenti 
tTA and a transfection control vector expressing Renilla luciferase. Upon transfection, the 
cells were maintained in the absence of Doxycycline for three days in order to aid Tet 
dependent transcription. Following this, the cells were cultured in media supplemented with 
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Doxycycline in the presence or absence of the NS5B polymerase inhibitor 2-CMA. 
Luciferase values were measured after 29 hours and 39 hours of incubation. 
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Figure 32: Testing the replication potential of the tet inducible plasmids. 
 
The Tet inducible plasmids JFH-1 and IFH-1ΔGDD were transfected in the presence of a lentiviral 
plasmid coding for the transactivator along with the reporter plasmid Mdic R-luc. Upon 
transfection, the cells were maintained in the absence of Doxycycline for three days. Following this, 
the cells treated with or without polymerase inhibitor (2-CMA). Luciferase values were measured 
and normalized to the Renilla luciferase values. 
 
These data showed an increased level of luciferase expression in cells transfected with the 
JFH1 plasmid in the absence of 2-CMA in comparison to the JFH-1ΔGDD. However, in the 
presence of 2-CMA, a polymerase inhibitor, the luciferase expression of the cells 
transfected with JFH1 construct was comparable to the cells transfected with JFH-1ΔGDD. 
This suggests that difference in luciferase levels observed between the two constructs in the 
absence of 2-CMA is due to the replication potential of the JFH1 construct. 
This indicates that the inducible JFH1 construct exhibits the potential to replicate using the 
viral polymerase NS5B whereas the JFH-1ΔGDD-prom3 is unable to do the same. 
This system has allowed for the generation of novel inducible HCV cell lines using which 
interferon stimulated genes induced at very early time points, such as immediately after the 
host recognizes the virus can be analyzed. 
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2.4 Chapter 4: HCV replication analysis in primary mouse 
hepatocytes 
Hepatitis-C virus is a largely hepatotropic virus. Although HCV research is carried out 
extensively on hepatoma cell lines, primary hepatocytes prove to be a good host system to 
study HCV infection or replication. Primary human hepatocytes have been widely used for 
analysis of pathology and toxicology. However, extensive research is limited due to limited 
sample availability, comparably low efficiency and reproducibility. Also, the role of 
individual proteins of the interferon response can only be carried out upon knocking down 
these effectors.  
Although primary murine hepatocytes are not naturally susceptible to HCV infection, they 
can be used to characterize the replication of tranfected HCV RNA. The use of primary 
murine hepatocytes in studying HCV replication has several advantages. Firstly, owing to 
the availability of mice strains deficient in specific essential proteins of the interferon 
system, the importance of these factors in HCV replication can be studied. Secondly, unlike 
hepatoma cell lines with mutated pathogen recognition receptors and the ensuing interferon 
response, primary hepatocytes have a fully competent interferon system unless otherwise 
altered. Since hepatocytes are highly differentiated cells, they must be cultured under 
stringent conditions to maintain their regular structure and physiology. A significant 
disadvantage of primary heaptocyte culture is its high propensity to de-differentiate into 
fibroblast-like cells
127
.  
 
2.4.1 HCV replication in WT hepatocytes 
The aim here was to investigate HCV replication in hepatic cells and to elucidate the role of 
the IFN system as restriction factors for HCV replication. 
Primary murine hepatocytes were isolated from WT mice and transfected with in vitro 
transcribed RNA from JFH-1 subgenoimc replicon as well as the polymerase mutant JFH-
1ΔGDD. Luciferase levels as a measurement of HCV replication were determined 5 hours 
post transfection and every day for the following 3 days.  
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Figure 33: HCV replication in WT primary hepatocytes  
Primary hepatocytes isolated from WT mice were transfected with JFH-1 (red line) or the 
polymerase deficient JFH-1ΔGDD (blue line) RNA. Luciferase values were measured at 5h post 
transfection (Day 0) as a read out for transfection efficiency and everyday for the next 3 days.  
 
As shown in Figure 33, luciferase expression dropped after 5 hours and did not increase in 
the days following lipofection. This indicates that HCV was unable to replicate effectively 
in WT hepatocytes. Since data presented in MEFs (Figure 9) discusses the inhibitory role of 
type I interferon, we tested if type I interferon was inhibiting HCV replication. To this end, 
we tested viral replication in hepatocytes derived from WT mice in the presence of 
neutralizing type I IFN antibodies. 
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Figure 34: Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in WT 
hepatocytes 
WT hepatocytes were transfected with JFH-1 RNA. The electroporated cells were cultured on 12-
well plates without (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α 
(4EA1) and IFN-β (7FD3). 
 
 
Despite the blocking of the type I interferon response, the same pattern was observed in 
cells treated with antibodies against type I interferon. This indicates that the WT 
hepatocytes could not maintain replication of tranfected HCV replicon RNA. These data 
reflect the data from WT MEFs where depletion of the type I interferon response could not 
rescue HCV replication.  
2.4.2 HCV replication in IFNAR
-/-
 hepatocytes 
In order to verify if type I interferon was the major restriction factor for HCV replication in 
mouse hepatocytes as was observed to be in fibroblasts, IFNAR deficient hepatocytes were 
tranfected with HCV RNA and replication potential was analysed. To this end, primary 
hepatocytes with a defective type I IFN receptor were transfected with RNA from the JFH-
1 subgenoimc replicon. Luciferase levels were determined 5 hours post transfection and for 
the following 3 days. 
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Figure 35: HCV replication in IFNAR deficient primary hepatocytes  
Primary hepatocytes isolated from IFNAR knock-out mice were transfected with JFH-1 (red line) or 
the polymerase deficient JFH-1ΔGDD (blue line) RNA. Luciferase values were measured at 5h post 
transfection (Day 0) as a read out for transfection efficiency and everyday for the next 4 days.  
 
 
Luciferase analysis indicative of transfected RNA was detectable 5 hours post transfection. 
However, the luciferase levels declined one day post transfection and remained 
undetectable at the time points measured suggesting that only low levels of replication 
could be maintained in the absence of a type I interferon response. 
Again, IFNAR knock-out cells transfected with JFH-1 RNA were cultured in the presence 
or absence of neutralizing antibodies against type I interferon and luciferase expression 
indicative of HCV replication was measured. 
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Figure 36: Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in 
IFNAR knock-out hepatocytes 
IFNAR knock-out hepatocytes were transfected with JFH-1 RNA. The electroporated cells were 
cultured on 12-well plates (red line) or with (blue line) neutralizing antibodies (2μg/ml) against 
IFN-α (4EA1) and IFN-β (7FD3). 
 
 
The presence of neutralizing antibodies to type I interferon did not further increase HCV 
replication in these cells. This indicates that although HCV replication is blocked in the WT 
cells, the key restriction factor may not be the type I interferon family. Instead, at this stage 
it could be hypothesized that in the liver, a type III interferon or the genes induced by this 
family could be the major inhibitor of HCV replication. 
2.4.3 The role of IRF-5, IRF-1 and MAVS in HCV replication 
inhibition 
Since it is known that both the type I and III interferons induce the same set of ISGs, unlike 
fibroblasts, in addition to type I interferon hepatocytes are also responsive to type III 
interferon. In order to test the type I IFN independent but type III IFN dependent role of the 
IRFs, cells defective in key elements of the interferon system were analyzed. To this end, 
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primary hepatocytes isolated from IRF-5 knock-out mice were analyzed for HCV 
replication. 
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Figure 37: HCV replication in IRF-5 deficient primary hepatocytes  
Primary hepatocytes isolated from IRF-5 knock-out mice were transfected with JFH-1 (red line) or 
the polymerase deficient JFH-1ΔGDD (blue line) RNA. Luciferase values were measured at 5h post 
transfection (Day 0) as a read out for transfection efficiency and everyday for the next 3 days.  
 
The isolated hepatocytes which were transfected with RNA from the JFH-1 replicon 
expressed luciferase levels 5 hours post transfection. The level of expression dropped 
drastically after day 1 to basal levels up to day 3 post transfection. Luciferase levels of 
polymerase positive replicon was comparable to the polymerase mutant strain (ΔGDD). 
This suggests that IRF-5 does not play a critical restrictive role in replication of HCV.  
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Figure 38: Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in IRF-
5 knock-out hepatocytes 
IRF-5 knock-out hepatocytes were transfected with JFH-1 RNA. The electroporated cells were 
cultured on 12-well plates (red line) or with (blue line) neutralizing antibodies (2μg/ml) against 
IFN-α (4EA1) and IFN-β (7FD3). 
 
Since the restrictive role of IRF-5 in HCV replication in the absence of an interferon 
response has been established in mouse embryonic fibroblasts (Figure 15) the role of an 
interferon independent role of IRF-5 in primary heaptocytes was tested. Primary 
hepatocytes isolated from IRF-5 knock-out mice were transfected with RNA from the JFH-
1 replicon and treated in the presence of antibodies against type I interferon and luciferase 
levels were measured up to day 3 post transfection.  
Although the level of luciferase expression dropped after one day post transfection, a 
slightly higher level of expression was maintained up to day 3 post transfection. The 
luciferase expression was not as high as that observed in mouse fibroblasts. Additionally, it 
is also possible that the low transfection efficiency compromised replication levels. 
Although, direct comparisons between different cell types do not deliver accurate results, 
these data indicate the possible function of a type I interferon independent response. 
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Similarly, the role of IRF-1 in HCV clearance has been well elucidated. In order to analyze 
the role of IRF-1 in HCV replication, primary hepatocytes isolated from IRF-1 knock-out 
mice were used. Primary hepatocytes isolated from IRF-1 knock-out mice were cultured 
and transfected with RNA transcribed from JFH-1 subgenoimc replicon or the polymerase 
mutant JFH-1ΔGDD. Cells were lysed at 5 hours post transfection and everyday for 3 days 
after that and tested for luciferase expression.  
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Figure 39: HCV replication in IRF-1 deficient primary hepatocytes  
Primary hepatocytes isolated from IRF-1 knock-out mice were transfected with JFH-1 (red line) or 
the polymerase deficient JFH-1ΔGDD (blue line) RNA. Luciferase values were measured at 5h post 
transfection (Day 0) as a read out for transfection efficiency and everyday for the next 3 days.  
 
As is shown Figure 39, no luciferase expression was observed in the replication competent 
JFH-1 transfected cells and was comparable to the polymerase mutant JFH-1ΔGDD. This 
indicates that IRF-1 does not play a restrictive role in HCV replication in mouse 
hepatocytes. 
Since the function of IRF-1 independent of type I interferon in mouse fibroblasts has been 
elucidated, their role in mouse hepatocytes was analyzed. To this end, IRF-1 knock-out 
hepatocytes were transfected with JFH-1 subgenoimc replicon and treated with or without 
antibodies against type I interferon.  
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Figure 40: Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in IRF-
1 hepatocytes 
IRF-1 hepatocytes were transfected with JFH-1 RNA. The electroporated cells were cultured on 12-
well plates (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α (4EA1) and 
IFN-β (7FD3). 
 
As shown, there was a slight increase in replication of JFH-1 in the IRF-1 knock-out mice 
in the absence of a type I interferon response. Replication was only slightly increased in the 
absence of a type I interferon response. This data indicated a role of a type I interferon 
independent IRF-1 dependent restrictive function in HCV replication. 
Additionally, the role of adaptor protein MAVS has been reported to be essential in 
maintaining a downstream interferon response
1
. MAVS is a protein localized on the 
mitochondrial surface and has been reported to be important in the restriction of HCV. In 
fibroblasts, MAVS has been reported to be an essential component in the IFN-λ pathway. 
Although IFN-λ is produced by several cell types not all cell components respond to this 
cytokine
128
. It is understood that both IFN-α and IFN- λ act together to limit viral infection. 
Cells treated with IFN- λ for a long time and then with IFN- α could completely abrogate 
viral replication in comparison to cells that were only treated with high levels of IFN- λ129. 
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To validate the role of MAVS adaptor protein in HCV replication, primary hepatocytes 
isolated from MAVS knock-out mice were transfected with in vitro transcribed JFH-1 or 
the polymerase deficient JFH-1ΔGDD RNA. The cells were lysed at 5 hours post 
transfection as a read-out for transfection efficiency and everyday for the following two 
days.  
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Figure 41: HCV replication in MAVS deficient primary hepatocytes  
Primary hepatocytes isolated from MAVS knock-out mice were transfected with JFH-1 (red line) or 
the polymerase deficient JFH-1ΔGDD (blue line) RNA. Luciferase values were measured at 5h post 
transfection (Day 0) as a read out for transfection efficiency and everyday for the next 2 days.  
 
As shown in Figure 41, luciferase expression could be observed up to day 2 post 
transfection. 
Since MAVS is pivotal in the ensuing interferon response, the role of MAVS in the absence 
of a type I interferon response in primary hepatocytes was determined. To this end, primary 
hepatocytes isolated from mice knocked-out for MAVS were transfected with RNA from 
the polymerase competent HCV JFH-1 strain and cultured in the presence or absence of 
neutralizing antibodies against type I interferon. 
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Figure 42: Replication analysis of JFH-1 in the presence of anti-Type I IFN antibodies in 
MAVS hepatocytes 
MAVS hepatocytes were transfected with JFH-1 RNA. The electroporated cells were cultured on 
12-well plates (red line) or with (blue line) neutralizing antibodies (2μg/ml) against IFN-α (4EA1) 
and IFN-β (7FD3). 
 
As was observed a higher level of luciferase expression was observed in cells cultured in 
the absence of a type I interferon response. This suggests that in hepatocytes, although 
MAVS was found to be essential in inducing an antiviral response against HCV, the 
abrogation of an IFN response elucidated a role independent of the type I interferon 
response.
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3. Discussion: 
 
3.1 Inhibitory role of the interferon system against HCV in 
mouse fibroblasts 
 
The Hepatitis-C is a virus that primarily affects the liver. HCV infects approximately 3% 
of the global population
11
. Patients chronically infected with the virus often progress to 
liver fibrosis, cirrhosis and eventually to hepatocellular carcinoma. Currently, there are no 
vaccines available against HCV, treatment regime is only partly successful and viral 
clearance is reported to be dependent on several viral and host factors. Studies towards an 
effective vaccine and treatment are hampered due to the lack of suitable models eg: small 
animal models. Limited host and tissue tropism of HCV has severely hindered the 
development of small animal models susceptible to HCV. Currently, the chimpanzee is the 
only animal model susceptible to HCV infection that can be used to study immune 
responses against a replicating virus. However, chimpanzee research is expensive, difficult 
and restricted by ethical constraints. Although HCV is largely hepatotropic, reports 
indicate the presence of virus particles in the B cells, the cerebrospinal fluid and the 
endothelium of the blood brain barrier etc
35,37
. Apart from hepatic cells, HCV is also 
reported to replicate in HEK, HeLa and MEF cells
38-40
. 
The current treatment regime for HCV is pegylated IFN combined with nucleoside 
analogue Ribavirin. Although the treatment is largely successful, not all patients achieve 
the desired sustained virological response
130
. Variations in treatment outcomes have been 
reported both within and across viral genotypes. Also, within the same genotype, different 
races of people have shown to respond differently
131
. This implies that although treatment 
outcome depends on the genotype of the virus, host factors are also responsible for 
determining response to IFN. This led us to analyze the role of the IFN regulatory factors 
in limiting HCV replication.  
IFN treatment is largely successful in patients and HCV infected cell culture can be ‘cured’ 
by treating with IFN. Curing cell lines of HCV by treating with IFN is plausibly due to the 
induction of ISGs. IFN stimulated genes induced by IFN can directly inhibit HCV. 
However, the mechanism of how these ISGs inhibit HCV is still largely unclear. Viperin is 
one such ISG that binds host protein hVAP-33 and inhibits HCV from replicating by 
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inhibiting its interaction with the viral NS5A
132
. Although the direct functions of several 
other ISGs in the inhibition of HCV are predicted, the exact mechanisms are still elusive. 
HCV has been reported to induce the IFN system. RIG-I and TLR3 are pathogen 
recognition receptors that are adept at recognizing specific pathogen signatures; the 5’ 
triphosphate characteristic to non-host RNA and the double stranded HCV replication 
intermediate respectively
120,133
. Viral recognition and PRR activation leads to subsequent 
stimulation of IFN stimulated genes that lead to a cellular antiviral response. 
An activated interferon system is a result of several activated intermediate factors that 
culminate in the transcription of antiviral genes. The interferon regulatory factors are 
mediators of such an interferon response. In order to elucidate the role of individual IRFs 
in limiting HCV replication, mouse embryonic fibroblasts deficient in IRFs and other 
known effectors were transfected with HCV RNA and replication potential was observed. 
Interestingly, like most viruses, HCV has developed mechanisms to evade a functional IFN 
response. The structural and non-structural proteins of HCV have been reported to inhibit 
HCV replication by cleavage of the adaptor proteins MAVS
1
 and TRIF
2
 blunting the RIG-I 
and TLR3 mediated immune responses. Additionally, STAT1 proteins important in 
amplifying the IFN response are effectively counteracted by the HCV proteins. 
Replication studies of HCV are largely performed on human hepatoma cells such as Huh7 
and its derivative Huh7.5. Hepatoma derived cell lines are both susceptible and permissive 
to HCV and have proven to be valuable cellular targets for replication and infection 
studies. Due to a mutation of RIG-I in Huh7.5
118
 and an added down regulation of TRL3 in 
Huh7 cells
2
, immune response towards HCV is limited to pathways excluding TLR3 in 
Huh7 and RIG-I and TLR3 in Huh7.5 cells. These lesions in the IFN pathway could be the 
reason for HCV permissivity. 
Although mouse cells are not naturally susceptible or permissive to HCV infection, 
replication has been observed in cell lines with a defective IFN system
40
. Since MEFs have 
a fully functional and competent IFN signalling system, transfection of HCV replicons or 
subgenoimc replicons into mouse embryonic fibroblasts enables the detection of host 
responses against the virus. Additionally, the availability of mouse embryonic fibroblasts 
with specific lesions in the proteins of the IFN system provides the opportunity to study 
their individual roles in restricting HCV replication. Conditionally immortalized fibroblasts 
allow convenient maintenance of cells in culture while transforming to a ‘primary like’ 
phenotype in the absence of permissive conditions. The results described in this study are 
based on the subgenoimc replicon that codes only for a part of the viral genome. Viral 
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infection studies require full genome expression and are not covered in this study owing to 
the additional requirement of entry receptors on the surface of mouse cells. 
HCV replication is reported to be enhanced in the presence of microRNA-122
40
. Liver 
specific miR-122 reportedly enhances the conformation of the homologous IRES element 
aiding in translation. MiR-122 also increases replication of HCV although the mechanism 
by which it does so is still elusive. Therefore, mouse embryonic fibroblasts expressing 
miR-122 permit enhanced replication and more importantly allow analysis of the IFN 
response directed against the viral genome. 
HCV isolates from patients replicate weakly, if at all in cell culture
134
. This led to the 
discovery of the replicon technology
78
. This system essentially codes for the viral genome 
along with the acquired mutations that enable replication and virus production in cell 
culture. The replicon system has been useful in studying the viral life cycle as well as in 
drug screening. However, replicons are available only for genotypes 1b and 2a and not for 
the other recognized genotypes limiting research to the use of only these strains.  
In this study, primary-like cells were used to investigate the restricting role of IFN-
dependent and IFN-independent mechanisms to HCV replication. 
To determine the role of the type I IFN system in the restriction of HCV replication we 
compared the replication of a subgenoimc genotype 2a strain (JFH1) luciferase replicon in 
the different knock-out fibroblasts. As observed in Figure 7, WT MEFs could not maintain 
continued replication, indicating restriction factors in MEFs with prohibit HCV replication 
in MEFs.  
 In contrast, MEFs with a defective IFN response (ie: with a non-functional type I IFN 
receptor) were incapable of a continued antiviral response with leads to HCV replication 
(Figure 9). This suggests that the IFN system is component in limiting HCV replication 
and indicates that restriction of HCV replication in WT MEFs was a result of a fully 
competent IFN system and not due to the absence of exclusive host factors. However, the 
role of such complementary factors in viral packaging, assembly and release may be 
important but are not studied here. 
IFN regulatory factors are transcription factors pivotal in relaying activation signals from 
cellular pattern recognition receptors to the nucleus and inducing an effective antiviral 
response. IRF-3, an important mediator of antiviral defence works downstream of the 
MAVS and TRIF mediated RIG-I and TLR3 signalling and directly binds to the promoter 
of IFNα4 and IFN-β genes as well as a subset of ISGs. In the absence of IRF-3, induction 
of an antiviral response mediated by RIG-I and TLR3 are inhibited. This lesion stunts the 
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IFN response significantly resulting in a blunted antiviral response. Deletion of IRF-3 in 
MEFs permitted replication of HCV, suggesting that IRF-3 plays an important restrictive 
role in HCV replication in mouse fibroblasts. Blocking of the IFN response pathway in 
these MEFs did not further enhance replication. IRF-3 can direct antiviral responses by 
either inducing ISGs, or by stimulating an IFN response. The depletion of type I IFN 
responses did not enhance replication suggesting that the type I IFN response plays no role 
in HCV inhibition. This implies that the direct ISG induction is sufficient to limit HCV 
replication. Additionally, the already high level of replication probably inhibits further 
replication. This indicates that the latent IRF-3 undergoes activation and results in an 
antiviral response and this response is independent of IFN amplification.  
IFN induced upon viral challenge binds to the IFN receptor inducing the transcription of 
antiviral genes such as IRF-7, which upon activation is responsible for the induction of the 
late IFN-αs and thereby the amplification of the IFN response. Experiments performed on 
MEFs deficient in IRF-7 exhibited no replication of HCV (Figure 13). The results indicate 
that the amplification of the type I IFN response by IRF-7 was not responsible to limit 
HCV replication. Therefore, IRF-7 may not be an important factor in limiting HCV 
replication. 
Taken together, the inability of WT and IRF-7
-/-
 MEFs to maintain replication indicates 
that the response to IFN has little effect on limiting HCV replication. However, inhibiting 
the IFN response in IRF-7
-/-
 MEFs resulted in a significant increase in HCV replication 
(Figure 27). The blunted IFN response along with the added lesion of IRF-7 permits the 
replication of HCV. 
Similarly, the role of IRF-5 in immune function is well established. In this study, mouse 
fibroblasts deficient in IRF-5 could not maintain HCV replication (Figure 15). This 
suggests that although IRF-5 is pivotal in antiviral defence, it is dispensable to HCV 
replication in mouse fibroblasts. The IRF-5 independent antiviral protection could be 
explained as a result of cellular immune responses induced by other IRFs and the 
subsequently induced ISGs.  
In addition, inhibition of the IFN response in IRF-5
-/-
 MEFs resulted in a sustained and 
detectable luciferase expression indicative of ongoing HCV replication. The data indicate 
that in the absence of an IFN response, the deletion of IRF-5 dampens the immune 
responses against HCV resulting in HCV replication.  
Since viruses have evolved to antagonize the IFN pathway, the antiviral pathways induced 
by IRFs may lead to the induction of antiviral genes. IRF-1 is involved in antiviral defence 
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and its role as an IFN-independent antiviral strategy has been well elucidated
5,116
. The SNP 
(-300AA) in the IRF-1 gene lead to a higher inducibiltiy of the gene and has been 
associated with better response to treatment in patients infected with genotype 1
115
. In 
addition, over-expression of IRF-1 inhibits HCV replication in vitro, indicating a critical 
role of IRF-1 in limiting HCV replication. However, MEFs lacking IRF-1 did not support 
HCV replication (Figure 16). A combined defect in IFN response as well as IRF-1 resulted 
in a significant increase in HCV replication (Figure 28). Therefore, in the absence of a 
functional IFN signalling, IRF-1 may have a potentially restrictive function in HCV 
replication. Interestingly, patients who develop auto antibodies against IFNs do not attain 
sustained virological response
135
. Mutated or dysfunctional IRF-1 in patients non-
responsive to IFN may be reason for viral persistence.   
The functional relevance of MAVS protein as an adaptor molecule in IFN signalling 
through the RIG-I and TLR3 pathways is well established
1
. NS3/4A protein of HCV 
mediated cleavage of human MAVS protein by HCV to circumvent the induction of the 
IFN response has been well characterized
1
. However, deletion of MAVS in mouse 
fibroblasts was not sufficient to permit HCV replication (Figure 19). Again, this indicates 
that although the RIG-I dependent signalling network was blunted, the TLR-3 mediated 
pathway functioning through TRIF was still functional and is probably sufficient to restrict 
HCV replication.  
Additionally, IRF-1
5,123
 and IRF-5
136
  are known to be responsible for stimulation of ISGs 
independent of IFN signals.  
Additionally, protein kinase R (PKR) has been reported to be pivotal to antiviral defence. 
Following binding to dsRNA, PKR dimerizes and undergoes autophosphorylation. Thus 
activated, PKR phosphorylates eukaryotic initiation factor 2 eIF2A suppressing the cellular 
translation machinery
137-139
. In order to circumvent the lack of the host translational 
machinery, HCV has developed a functional IRES element. The IRES element aids in 
ribosome-mediated translation of the viral proteins. This suggests that PKR functions in 
inhibiting HCV replication in a manner independent of the type I IFN response. Because 
PKR expression is dependent on type I IFN, depletion of constitutive levels of type I IFN 
could reduce PKR expression and therefore PKR dependent restriction of HCV replication. 
Apart from the IRFs, IFN stimulated genes have been reported to be pivotal in anti HCV 
defence. STAT1 is a protein that acts downstream of the IFN receptor and is responsible 
for IFN amplification. This complex translocates to the nucleus and induces genes 
responsive to STAT1 binding. Additionally, STAT1 has been shown to be important in 
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restricting HCV replication
140
. Therefore it is not surprising that HCV has evolved to block 
the STAT1 activation pathway and the subsequent downstream signalling. The core protein 
of HCV has been shown to associate with STAT1 and induce degradation in a proteasome-
dependent manner
113
. Additionally, the HCV NS5A has been observed to inhibit STAT1 
phosphorylation, suppressing nuclear translocation and the ensuing IFN response
3,113
. 
Replication analysis of HCV in STAT1 knock out MEFs showed detectable levels of 
luciferase expression indicating that a lesion in STAT1 is sufficient to maintain HCV 
replication in these cells (Figure 12). 
HCV RNA harbours specific structures which are recognized by the cells as PAMPs and 
results in the induction of a type I IFN. Induction of IFNs were observed in MEFs 
transfected with the JFH-1ΔGDD RNA, but the polymerase competent JFH-1 RNA was 
observed to induce significantly higher levels of IFN. This observation was plausibly due 
to the double stranded replication intermediates
63
 or due to the higher levels of RNA as a 
result of ongoing replication. 
 A higher induction of IFN was observed in WT MEFs as compared to all other transfected 
cell types (Figure 20). This could be the plausible reason why HCV could not replicate in 
these cells. These data suggest that replication must occur at the very early stages in WT 
cells, but the induced IFN response is sufficient to inhibit replication. This could explain 
the lack of replication in WT MEFs in spite of the deleted IFN response. Cell lines such as 
IFNAR and IRF-7 induce lower amounts of IFN (Figure 21) which could be due to the 
absence of the IFN amplification loop. The role of type I and III IFNs have been shown to 
be important in inhibiting HCV. Type III IFN/ IFN- lambda has been shown to have 
inhibitory effects on HCV in human hepatoma cells
141
. IL28B is associated to viral 
resistance and is known to be upregulated by IFNs and by HCV infection
101
.  Two SNPs 
located near the gene region encoding IFN-λ3 (rs12980275 and rs8099917) in HCV 
infected patients treated with the combination therapy has been associated to treatment 
outcome
101,102
. 
However, in MEFs, it was observed that HCV restriction is solely dependent on the type I 
IFN because IFN response could be completely blocked by anti type I IFN (Figure 21).  
Since, type I IFN were observed to be induced in MEFs transfected with HCV the role of 
these individual factors independent of the IFN response was analyzed. To this end, WT 
and IFNAR knock out MEFs were electroporated with RNA transcribed from the JFH-1 
strain and were cultured in the presence or absence of neutralizing antibodies against type I 
IFN. In the absence of an IFN amplification loop, no HCV replication was observed in WT 
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MEFs suggesting that the competent endogenous IFN levels and ISGs in the cell was 
sufficient to limit HCV replication. No additional replication was observed in the IFNAR 
knock out MEFs.  
WT cells induce higher amounts of IFN in response to HCV than IFNAR and IRF-7, which 
could be due to the lack of amplification loop in the absence of IFNAR and IRF-7. The 
higher amounts of IFN secreted by WT MEFs in response to HCV could be the reason for 
the inhibition of HCV replication. In order to test this, replication assays were performed in 
the presence of depleting antibodies to type I IFN. WT cells permitted no replication of 
HCV indicating that other mechanisms were important.  
However, depletion of type I IFN in IRF-1, IRF-5 and IRF-7 deficient cell lines revealed a 
significantly high replication level indicating the important restrictive functions of these 
factors in HCV replication inhibition. Replication levels were also higher in PKR and 
MAVS deficient MEFs. 
Taken together, the inability of WT MEFs to maintain replication indicates that in the WT 
MEFs, the response to IFN has little effect on limiting HCV replication. The ability of 
IFNAR knock out MEFs to support HCV replication could be attributed to plausibly low 
levels of endogenous IFN and the subsequent decrease in IFN stimulated gene expression.  
The absence of individual proteins IFNAR, IRF-3, PKR and STAT1 were shown to 
enhance HCV replication. However, IRF-1, IRF-5 and IRF-7 were dispensable in limiting 
HCV replication.  Surprisingly, the loss of IRF-1, IRF-5 and IRF-7 in MEFs in the absence 
of a type I IFN response resulted in significantly higher expression of luciferase indicative 
of active replication.  These data indicate the additional roles of IRF-1, IRF-5 and IRF-7 in 
limiting HCV replication in the absence of IFN response.   
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3.2 Inducible cell lines for analyzing virus-host interactions 
at very early time points 
 
HCV is a poor inducer of IFN, an aspect that can be attributed to the many ways the virus 
has evolved to evade the host IFN machinery. HCV viral proteins have evolved techniques 
to either cleave
1,2
 or successfully escape
3
 host proteins essential in the induction of IFN 
responses. Evidence from studies on experimentally infected chimpanzees suggests that the 
time point and kinetics of ISG induction could help determine disease outcome, 
chimpanzees which show high ISG expression levels at early time points of infections 
clear HCV infection more efficient whereas a later ISG response is associated with 
development of chronic HCV
100
. This indicates that the detection of ISGs induced at very 
early time points can prove to be markers for progression to chronic infection or the 
resolving of infection at the acute stage itself. Thus, the it is important to study such 
responses in cell lines at very early time points. To this end, the inducible HCV replicon 
was generated along with a separate polymerase mutant plasmid that serves as a replication 
deficient control. The novelty of these plasmids lies in the fact that when single cell clones 
are generated, not only can the transcription be controlled exogenously but the cellular 
response is largely synchronous. This advantage is of great importance in the detection of 
genes only mildly induced that are otherwise lost in transient transfections where only a 
population of cells are transfected. Since the inducibility of these plasmids has been 
elucidated, it is evident that a technology wherein HCV can undergo controlled 
transcription has been generated. Additionally, the ability of the polymerase competent 
plasmid to replicate using the viral NS5B RNA dependent RNA polymerase (RdRp) allows 
the virus to replicate in culture. This is of utmost importance as viral replication and the 
double stranded intermediate formed in the process have been reported to induce IFN 
stimulated genes
133
. The comparison of the replicating RNA to the polymerase negative 
control will provide us information about the IFN stimulated genes induced upon 
replication. 
Taken together, this system is an excellent tool to analyze the virus-host interaction with 
time. 
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3.3 Inhibitory role of the IFN system against HCV in mouse 
hepatocytes 
 
Until recently much of HCV research was carried out on hepatoma cell lines which have 
known lesions in the receptors of IFN signalling. Owing to this defect, observations made 
on these cell lies do not provide an accurate representation of virus host interactions and 
responses thereby. To circumvent this, human fetal liver cells (HFLC) as well as primary 
human hepatocytes (PHH) have been used for investigations on host-virus interactions.  
Since it was identified using fibroblasts that a strong IFN system could effectively block 
HCV replication; the role of the type I IFN as the dominant restriction factor for HCV 
replication in primary hepatocytes was analysed. HCV subgenomic replicons are not able 
to replicate in primary hepatocytes isolated from WT mice. In addition, neutralization of 
type I IFN does not allow HCV replication. Surprisingly, IFNAR-/- MEFs allow 
replication of HCV RNA, may be due to a lower basal expression of antiviral genes in 
IFNAR-/- cells. To test if this hypothesis is true for primary hepatocytes, hepatocytes 
isolated from mice defective in the type I IFN response were transfected and replication 
potential in these cells were analyzed. An insignificant rise in replication was observed in 
these cells (Figure 35) suggesting that in contrast to MEFs, replication inhibition of HCV 
in hepatocytes was not mainly due to the type I IFN response. This indicates that the 
restrictive mechanisms working against HCV in hepatocytes have a low dependence on 
type I IFN. It has been reported that in spite of the separate, distinct receptor that IFN-λ 
uses, pegylated IFN-λ was capable of inducing an identical antiviral response as type I 
IFN
142
. This is further corroborated by the fact that IFN-λ is currently in clinical trials for 
HCV clearance. 
The type III IFN family is the most recent of the identified IFN families. Type I and III 
interferons induce a similar set of ISGs
142
, probably due to the induction of similar 
STATs
143
. Unlike the type I IFN that all nucleated cells can secrete and respond to, the 
type III IFN or the IFN-λ family show tissue specific responses. The type III IFN family 
has been shown to be largely epithelial cell specific
144
. In addition to being differentially 
induced, it is also implied that type III IFN signalling may be resistant to viral feedback 
mechanisms targeting type I IFN loops
145
.  
The IL28B locus has been reported to be an important marker for disease treatment 
outcome
101-103
. Why and how patients with a particular IL28B SNP clear the virus better is 
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still elusive. A detectable level of ISG induction is reported in the livers of patients with 
acute and chronic HCV although detection of IFN-β may not be detected65,146.  
It was observed that hepatocytes isolated from WT mice with a healthy IFN signalling 
system did not permit HCV replication (Figure 33). Additionally, blocking of the type I 
IFN response did not enhance replication and the luciferase levels indicative of replicating 
virus remained undetectable (Figure 34). These data suggest that replication must occur at 
the very early stages in WT cells, but the induced IFN response was sufficient to inhibit 
replication.This suggested that a strong IFN system from the host was inhibiting 
replication of HCV. 
In addition to type I IFN, MAVS has been shown to regulate IFN-λ genes147, therefore it 
could be hypothesized that the antiviral responses directed against HCV may share the 
same regulatory factors as type I IFN. In line with this data, hepatocytes with a defective 
MAVS protein seemed to maintain HCV replication (Figure 41). This phenotype was 
exaggerated when the type I IFN response was ablated (Figure 42). Replication of HCV 
observed in MAVS knock-out hepatocytes suggest that MAVS is pivotal in anti HCV 
defence and increased replication in the absence of a type I IFN response suggests a type I 
IFN independent function of MAVS protein. Since MAVS has been shown to regulate 
IFN-λ genes147, it is not surprising that elevated replication levels could be observed in 
MAVS deficient cells. Additionally, in the context of VSV, a novel dependence on MAVS 
localization was studied. Peroxisomal MAVS were observed to induce interferon-
independent antiviral factors that provide immediate but short-lived protection whereas, 
the mitochondrial MAVS paved way for a delayed but longer antiviral response
123
. Since 
IFN-λ has been shown to induce a similar set of ISGs as type I IFN141,142, and since IFN-λ 
activates STATs similar to IFN-α/β in vitro, the potential role of individual IRFs in viral 
clearance was studied. Replication assays performed on IRF-1 knock-out hepatocytes 
revealed that IRF-1 did not play an important role in limiting HCV replication (Figure 39). 
Also, in the absence of a type I IFN response an increase in replication was observed 
(Figure 40). Since IRF-1 has been indicated to be important in HCV restriction, studies on 
hepatocytes with deleted IRF-1 and MAVS (double knock-out) protein could further 
elucidate the importance of these factors in viral restriction. 
Similarly, replication assays performed on hepatocytes from IRF-5 knock-out mice 
revealed that IRF-5 did not play a pivotal role in restricting HCV replication (Figure 37). 
However, a slight effect of IRF-5 was observed in the absence of a type I IFN response 
(Figure 38) suggesting a type I IFN-independent restrictive function in HCV replication. 
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Taken together, the data indicate that HCV replication in mouse hepatocytes is restricted 
by a strong IFN response largely independent of the type I IFN response. Therefore, this 
could indicate the presence of a dominant type III IFN response against HCV in 
hepatocytes. Whether type III IFN dependent or independent factors act as dominant 
inhibition factors in HCV restriction will have been studied in the context of a depleted 
type III IFN response.  
These data indicate that although responses dependent and independent of type I IFNs are 
pivotal in antiviral defence in fibroblasts cell lines, in the hepatocytes the type III IFNs 
may play an important restrictive role. 
In line with these findings, recent reports on experimentally infected chimpanzees showed 
that type III IFNs but not type I IFNs mediated ISG induction and antiviral response in 
hepatocytes
70
. Considering the similar sets of ISGs induced by both type I and III IFN 
families
141,142
, the reason behind a strong type III IFN response could be the stimulation of 
an antiviral response in the event of an impaired type I response mediated by viruses.  
Additionally, it is also argued that like type I IFN, IFN-λ could be important in 
differentiation and maturation of DCs. 
 
 
 
 
 
OUTLOOK 
81 
 
4. Outlook  
 
The function of the IFN system has proven to be indispensible in limiting Hepatitis-C virus 
infection. This thesis identifies the importance of the IFN regulatory factors and IFN 
stimulated genes in restricting replication of HCV. Since mouse cells are not susceptible to 
HCV infection, only factors restricting replication of the subgenoimc replicon could be 
identified with this experimental set-up. The host system has been reported to be adept at 
restricting entry as well as budding and release of virus particles. In order to identify host 
factors restricting these crucial stages, mouse cells must be made susceptible to infection. 
The entry receptors required for HCV infection have been identified as scavenger receptor 
class B member protein SR-B1, tight junction proteins occludin and claudin as well as CD-
81, a member of the tetraspanin family of proteins. Although the murine versions of 
claudin and SR-B1 are functional, mouse cells have to be complemented with the human 
versions of CD-81 and occludin to successfully aid in HCV entry.  
Expression of these entry factors in mouse cells can serve as an infection model enabling 
the elucidation of an IFN response against HCV. With this model, additional restrictive 
roles of the IFN regulatory factors or IFN stimulate genes on the entry or budding and viral 
release can be defined. The determination of host factors aiding in limiting HCV 
replication by induction of a strong IFN response could lead to increased understanding of 
response to treatment and disease outcome. 
The analyses of IFN stimulated genes in the established stable replication competent cell 
lines expressing HCV can be determined. An assessment of gene induction at the very early 
time points can also be determined. 
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5. Material and Methods: 
 
5.1 Chemicals 
The chemicals used for the purpose of this study were supplied by the following 
companies: Amersham Biosciences, Bayer, Bioline, BioRad, BRL Difco, Gibco, Merck, 
Promega, PAA, Qiagen, R&D systems, Roche, Seromed, Serva and Sigma.  
Enzymes were purchased from Bioline, Invitrogen, New England Biolabs (NEB), 
Promega, Roche and oligonucleotides were synthesized at Eurofins MWG Operon. 
Antibodies were purchased from eBioscience, Pharmingen and Beckton Dickenson. 
 
5.2 Consumables 
 
Table 1 :List of Consumables - 
Article Company 
Cell culture plates(24 well,12 well, 6 well) Nunc, Corning,  
Tissue culture dishes Corning, Greiner Bio-one 
Reaction tubes (15ml, 50ml) Greiner Bio-one 
Flow cytometry tubes Sarstedt 
Tissue culture flasks(25cm2 ,75cm2 ,125cm2) Corning, Greiner Bio-one 
Combi tips Eppendorf 
Safe lock tubes Eppendorf 
PCR tubes  Kisker Biotech, Steinfurt 
Cryovials Corning 
 
5.3 Equipment 
 
Table 2: List of Equipments - 
Article Company 
Analytical balance Sartorius Model 120S / 500G 
Autoclave Belimed Dampsterilizer 6-6-6 HS1,FD Tecnomara 
Table-top autoclave Technoclav 50  
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CCD-Camera  Nikon Coolpix 4500  
Cell counter Schärfe System Casy 1 DT 
Cell Sorter FACS Aria, Becton Dickinson 
Cooling centrifuge Sorvall super speed RC5-C  
Deionized water supply Millipore Milli-Q 
Electroporator Gene Pulser Xcell, BioRad 
Freezer -20 °C: Liebherr Model GS3183 -80 °C: GFL 6485  
Fridge Liebherr Model UKS3600  
Incubator for cell culture Forma Scientific Model 3336 Labotec C200 
Shaker Heidolph REAX3  
Light cycler Roche 
LSR II Becton Dickinson  
Microscope Leitz Labovert FS Olympus Type CKX41 und CK2  
Microwave Whirlpool Model Pro 825  
Mini centrifuge Heraeus-Christ, Biofuge fresco 
Nitrogen tank HarscoK-Series Modell 17K  
PCR machine Biometra T3 Thermocycler 
pH-Meter  Beckmann M340  
Photometer Thermo Electron Corporation, Multiskan EX  
Pipettes Gilson Pipetman Labnet Biopette  
Pipettor Pipetboy IBS Integra Biosciences  
Power Pack Biorad Power Pac 300 
Refrigerated centrifuge    Juan ModellCR412  
Spectral photometer  PeqLab Nanodrop ND-1000  
Table centrifuge Heraeus Biofuge pico Heraeus Sepatech Megafuge 1.0R  
Thermo shaker Eppendorf Model compact  
Vortex Heidolph REAX 2000 
Ultra centrifuge Sorval Combi OTDC;  rotor Beckman T150, T10 
Water bath Rowa Model Ro 3044 
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5.4 Software 
This thesis was written using the Microsoft (MS) Word 97-2003 version.  Tables, 
calculations  and graphs  were  constructed  on  MS  Excel  97-2003  as  well  as Graph pad 
PRISM and Sigma Plot version 11.  Figure design and annotation was performed with MS 
PowerPoint 97-2003.   Microscopical image analysis was performed with ImageJ (National 
Institutes of Health) and the corresponding plugins as well as Zeiss LSM510 software. 
Flow  cytometry  data  was  acquired  and  analyzed  with  BD  CellQuest,  BD FACSDiva 
and FlowJo v7.6 . Vector NTI Advance 4/10/11 was used for in-silico cloning, sequence 
alignment and primer design. Primer3 was used for primer design. Sequencing results were 
analyzed with Chromas version 2.32 (Technelysium Pty Ltd.  Quantitative PCR (qPCR) 
results were analyzed and calculated using the LightCycler 480 software. 
 
5.5 Sterilization 
Glassware was sterilized at 180˚C for 4 hours prior to use. Plastic materials such as 
Eppendorf tubes, pipette tips and solutions for cell culture were autoclaved at 121˚C for 25 
minutes. Solutions that could not be autoclaved were filtered through a 0.22μm filter under 
a clean working bench.  
 
5.6 Photometric determination of nucleic acid concentration 
Concentration of nucleic acids was assessed by measuring absorbance at A260 on a 
Nanodrop-1000. Purity of nucleic acids preparation was determined by the A260/280 ratio. 
A value appreciably lower than 1.8 and 2 for DNA and RNA respectively indicates a 
contamination due to protein, phenol or organic compounds in the sample. 
 
5.7 In vitro transcription and RNA preparation 
For elctroporation, plasmid DNA was linearized, in vitro transcribed and purified. To this 
end, 10ug each of pJFH1 and pJFH1ΔGDD were linearized using Mlu1 restriction enzyme 
(NEB) at 37˚C for 1 hour. The linearized DNA was extracted in the presence of 1/10 
volume of 3M sodium acetate (pH5.4) and 200ul of cold phenol equilibrated with TE. 
Upon centrifugation, at 13500rpm for 3 min the supernatant was extracted and the step was 
repeated. Following the extraction of the supernatant in the first tube 200ul of ddH2o was 
added and subjected to second round of centrifugation in order to extract any DNA still 
MATERIALS AND METHODS 
85 
 
remaining. Finally, an equal volume of chloroform was added to the supernatant and 
centrifuged again at the same conditions. Again, the supernatant was separated and 2.5 
volumes of 100% ethanol was added and stored at -20˚C for 1 hour or overnight. After this, 
the tube was centrifuged at 13500rpm for 20 minutes at 4C.  The DNA pellet was then 
washed with 80% ethanol and dried briefly at 37˚C. The ethanol-free pellet was dissolved 
in 50ul RNAse-free water. The concentration of linearized DNA was quantified using the 
Nanpdrop.  
The linearized DNA was subsequently subjected to in vitro transcription in the presence of 
5X RRL buffer (400mM HEPES pH 7.5; 60mM MgCl2, 10mM Spermidine, 200mM 
DTT), 25mM rNTP, 40U/μl RNAse inhibitor, and 80U T7 polymerase and incubated for 
2hours at 37C. Following this, 2U of T7 polymerase was added additionally and incubated 
again for 2hours at 37C. Finally, 2U/μg of DNAse was added and incubated for 30 minutes 
at 37C. 
The RNA thus transcribed was extracted using 2M sodium actetate (pH 4.5) in the 
presence of water and aqua saturated phenol (pH<5). The mixture was vortexed and 
incubated on ice for 10 minutes. The reaction mixture was then centrifuged at 13500rpm 
for 10 minutes at 4C. The supernatant obtained following centrifugation was mixed with 
equal volume of chloroform and subjected to another round of centrifugation for 3minutes 
at 13500rpm. RNA was precipitated from the supernatant by adding 0.7 volumes of 
isopropanol equilibrated to room temperature. Finally, the mixture was centrifuged at 
13500rpm for 15minutes at room temperature and the pellet thus obtained was washed 
once with 70% ethanol. Once briefly air dried, the pellet was resuspended in 50ul RNAse 
free water and the concentration measured on the Nanodrop. 
 
5.8 Isolation of murine cells 
 
5.8.1  Mouse embryonic fibroblasts 
MEFs were isolated from mice E13.5-14.5 post coitus. During this stage of gestation, the 
developing organs are coalesced making it easier to discard. E13.5 embryos were 
decapitated and the heart, lungs and abdominal organs were scooped out and the remaining 
mesenchyme surrounding the somites which is the source of most fibroblasts was obtained 
by digesting in Trypsin for 30minutes at 37˚C and plating in DMEM 3+ as mentioned 
above. 
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5.8.2 Primary mouse hepatocytes 
To obtain fresh mouse primary hepatocytes, 6-8 week old male mice were anesthetized 
with 0.1ml/10g body mass of ketamin(10%) xylazine(5%) NaCl(85%). Upon sedation, an 
incision was made on the skin exposing the abdominal region. The peritoneum was briefly 
rinsed with 70% ethanol following which it was cut open to expose the liver and the 
abdominal region. The intestines were carefully shifted to the side exposing the hepatic 
portal vein and the inferior vena cava. An intravenous canula was carefully inserted into 
the vena cava and the liver perfusion media supplemented with heparin (500U/ml) was 
injected at a flow rate of 8ml/min to flush out all non-resident liver cells. Liver digest 
media supplemented with collangenase (55mg/150ml) was allowed to flow at a constant 
flow rate of 25ml/min at a temperature of 37˚C. The digested liver was excised and 
hepatocytes were gently released from the liver. Liberated cells in suspension were then 
separated from any remaining undigested tissue by filtering through a polyester gauze 
mesh with 100 µm apertures. The cell suspension was centrifuged at 300rpm for 5 minutes 
and the pellet washed again with a large volume of medium. Briefly, 20 µl of the cell 
suspension was added to 20 µl of Trypan Blue dye in a sterile capped tube and inverted 
briefly to mix.  This mixture was introduced, into the chamber of an Improved Neubauer 
haemocytometer and the  chamber  was  examined  by  light  microscopy  at  100x  
magnification. Total hepatocyte  numbers  were  counted  in  the  entire   1 mm  delineated  
field  of  the haemocytometer and seeded in the desired concentration on collagen-coated 
plastic ware.  
 
5.9 Manipulation of murine cells 
 
5.9.1 Production of lentivirus  
Lentiviral vector production was performed by transient transfection of plasmids PLP1, 
PLP2 and VSV-G encoding helper functions along with the expression cassette in 293T 
cells as described previously 
106
. 
5.9.2 Conditional immortalization of MEFs 
With subsequent sub culturing, primary cells lose replicative potential and proceed towards 
Hayflick’s limit; a point after which cells undergo senescence and die. Immortalised cells 
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often replace primary cells in routine studies as these cells expressing certain oncogenes 
continue to proliferate even after repeated passaging.  Owing to the disadvantages of 
maintaining primary cell cultures, and the plausible changes induced by induction of the 
oncogenes a strategy called ‘Conditional immortalization’ was developed. Conditionally 
immortalized cells contain oncogenes that are activated upon induction but retain ‘primary 
like’ phenotype otherwise. To generate immortalized MEFs, 2 wells of a 6-well dish were 
plated with the desired cell line and one was transduced with lentivirus coding for SV40 
large T antigen while the other well was left untransduced. The transduced cell line was 
termed ‘immortalized’ when upon repeated sub-culturing the primary cells had lost 
replication potential and ceased to grow as compared to the transduced cell line which in 
the induced state continued to proliferate. 
 
5.9.3 Lentiviral transduction of miR122 in MEFs 
2x10*5 MEF cells were seeded on a 12-well plate, one day after which the media was 
aspirated and 500ul of lentivirus stock solution supplemented with 4mg/ml Polybrene was 
added to the cells. After over-night incubation, the cell monolayer was washed once with 
1x PBS and replenished with fresh media. 
 
5.10   Culture and manipulation of E.coli 
 
5.10.1 E.coli laboratory strains 
Table 3: List of Bacterial strains - 
E. coli strain Genotype 
DH10B F',  mcrA,  (mrr  hsdRMS-mcrBC),  Φ80dlacZ  M15,  LacX74,  deoR, 
recA1, ara139, galU, galK, λ - , rpsL, endA1, nupG (Gibco BRL)   
TOP10 F-  mrcA  ∆  (mrr-hsdRMS-mcrBC)  Φ80dlacZM15,  ∆lacX74  recA1  
araD139 ∆ (ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG    
INV110 F ´ (traΔ36 proAB lacIq lacZΔM15) rpsL (StrR) thr leu endA thi-1 
lacY galK alT ara tonA tsx dam dcm supE44 Δ(lac-proAB) Δ(mcrC-
mrr)102::Tn10 (TetR) 
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5.10.2 Culture media and antibiotics 
Table 4: List of Culture media - 
Bacterial Medium Composition 
Lysogeny Broth (LB) 
1 % (w/v) tryptone, 0.7 % (w/v) NaCl, 0.5 % (w/v) yeast 
extract, adjusted to pH 7.5 with NaOH 
LB-Agar LB, 1.5 % (w/v) agar-agar 
Ampicillin    
Stock solution: 5 mg/ml in ethanol, filtered sterile   
5 µg/ml in LB-medium   
25 mg/ml in agar culture plates   
Kanamycin    
Stock solution: 5 mg/ml in double distilled water, filtered sterile   
2.5 µg/ml in LB-medium   
12.5 µg/ml in agar culture plates   
Agar culture plates    
15 g of solid agar in 1 L of LB-medium was autoclaved under conditions mentioned above 
and poured into plates with the required antibiotic. 
 
5.10.3 Preparation of chemocompetent E.coli strain 
Cells were grown at 37°C, 180 rpm  until the cell suspension had reached an OD 600  
between  0.6 – 0.8. Subsequently,  cells  were  centrifuged  for  5 - 10  min  in  a cooled  
centrifuge  at 1,500  rpm.  The  cell  pellet  was  resuspended  in  cold  sterile water, 
washed twice with  cold  sterile water  and once with 10% glycerol. Finally, bacterial cell 
pellet was resuspended in appropriate amounts of 10% glycerol and stored immediately at -
80° C.  
 
5.10.4 Chemical transformation of DNA into E.coli 
TOP10 cells frozen at -80°C were thawed gradually on ice.  50ng of DNA was added to the 
thawed cells and heat shocked at 37°C for 10 minutes. The cells were placed on ice for 5 
minutes after which the cell suspension was incubated at 37°C in the presence of 1ml LB 
media. Subsequently, the suspension was spread on to agar culture plates containing the 
antibiotic corresponding to that carried as a resistance gene in the plasmid. 
 
5.10.5 Preservation of bacterial strains 
For  short-term  storage,  E. coli  was  cultured  over-night  at  37°C  on  agar  plates    and  
subsequently    kept    at    4°C.    For long-term storage, the bacterial suspension was 
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mixed with 87% glycerol solution in a ratio of 1:1 and preserved in glass vials at -20°C or -
80°C.   
 
5.11   Culture and manipulation of eukaryotic cells 
 
5.11.1 Cell lines 
 
Table 5: List of Cell lines - 
Cell line Descrption 
1˚ MEFs Primary Mouse embryonic fibroblasts 
Conditionally 
immortalised MEFs 
Murine Fibroblasts immortalised with SV40 large T antigen 
1˚m.hepatocyte Primary murine hepatocytes 
 
5.11.2 Culture media and reagents 
 
Table 6: List of Culture media and Reagents – 
 
Medium Composition 
Dulbecco's Modified 
English Media (DMEM) 
13.63  g/L  DMEM  powder (Sigma),  3.67  g/L  (44mM) 
NaHCO3, 2.6g/L 10mM HEPES, pH 7.2   
Phosphate buffered Saline 
(PBS) 
140 mM NaCl, 27 mM KCl, 7.2 mM Na2HPO4 , 14.7mM KH2PO4 , 
pH 6.8-7.0 
Trypsin EDTA PBS 
(TEP) 
6mM EDTA, 0.1% trypsin (Gibco) in PBS 
100 x Pen/Strep            
6.06 mg/ml ampicillin (10,000 U/ml), 10mg/ml streptomycin, 
pH  to  7.4  with NaOH and stored at -20°C 
100x Non essential 
amino acids 
Supplied by Gibco 
Fetal Calf Serum (FCS) Supplied by PAA 
G418     100mg/ml G418 in water, filtered sterile, (stored at  -20°C) 
Puromycin       5 mg/ml in water, filtered sterile, (stored at -20°C) 
   
DMEM 3+E for hepatoma cells: 
DMEM, 1 x Pen/Strep, 1 x Glutamine, 10% FBS, 1x Non essential amino acids 
Intestinal Epithelium Media: 
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DMEM/HAM F12 (1:1), 1 % Glu, 1 % PenStrep, 2 % FCS, 20 mM HEPES, 5 µg/ml 
Insulin (Sigma), 5 µg/ml humanes Apo-Transferrin (Sigma), 50 nM Dexamethasone 
Media for MEFs: 
DMEM, 1 x Pen/Strep, 1 x Glutamine, 10% FBS 
 
5.11.3 Cell cultivation 
Cells were maintained in DMEM media supplemented with 10% Penicillin and 
Streptomycin, 10% L-Glutamate, 10% Non-essential amino acids in addition to 10% Fetal 
bovine serum. These cells were maintained in an incubator at 37˚C and 5% CO2 and 
maximal relative humidity. Cells were sub-cultured every 3-4 days. To sub-culture, cell 
monolayers were washed with PBS and then Trypsinized for a few minutes at 37˚C until 
the cells dislodged from the primary culture vessel. The resultant cell suspension was 
counted and seeded further in the desired concentration. 
 
5.11.4 Estimation of cell density 
Cell suspension to be analyzed was diluted in Trypan blue (1:10). 10μl of the mixture was 
added to the chamber by gently resting the end of the tip at the edge of the chambers.  Cells 
in 5 square segments were counted and the average was used to determine the total cell 
count. The formula used was as follows: 
Cells density (per ml) = X (average cell count)*5*(multiplication factor)*10(dilution 
factor) 
Multiplication factors: 1000- Neubauer Chamber  or 5000- Fuchs-Rosenthal chamber  
 
5.11.5 Long term preservation of cells 
Cryopreservation is performed to preserve cells for long term storage and is carried out by 
gradual cooling in the presence of a cryoprotective agent like Dimethylsulfoxide. Gradual 
freezing reduces the risk of ice crystal formation and cell damage. To this end, trypsinized 
cell suspensions were centrifuged at 1000rpm for 5 minutes and the cell pellet obtained 
was resuspended in 10% DMSO diluted in cold FBS. The mix was then transferred into 
cryovials and stored in an ice box for an hour, after which, they were transferred to a -20˚C 
freezer for 2 days. Following this, the vials were then transferred to a liquid Nitrogen 
chamber for long time preservation.   
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In order to thaw cells preserved in a liquid Nitrogen chamber, the cryovials were thawed 
immediately by plunging vials into a 37˚C water bath. The vial was then washed with 
Ethanol and the cell suspension was resuspended in optimal media. The suspension was 
then centrifuged at 1000rpm for 5 minutes and the cell pellet thus obtained was added to 
fresh media and seeded on appropriate cell culture dishes. 
 
5.12    Nucleic acid transfection into cells 
 
5.12.1 Plasmid DNA transfection 
Lipofection was carried out on Huh7 and Huh7.5 cells that were seeded at a concentration 
of 5x10*5 on 12-well plates and transfected as per guided protocol provided in the 
Lipofectamine2000 kit by Invitrogen. 
 
5.12.2 RNA transfection by Lipofection 
Lipofection was carried out on Huh7, Huh7.5 and primary hepatocytes that were seeded at 
a concentration of 5x10*5 on 12-well plates and 3μg RNA was transfected per well 
according to the protocol provided in the Lipofectamine2000 kit. 
 
5.12.3 RNA transfection by electroporation 
 1x10*7 cells (Huh7 cells and fibroblasts) and 1.5x10*7 cells (Huh7.5 cells) were mixed 
with 2mM ATP and 5mM L-glutathione at a final volume of 400μl of cytomix (120 mM 
KCl; 0.15 mM CaCl2; 10 mM K2HPO4/KH2PO4 (pH 7.6); 25 mM Hepes (Gibco, cell 
culture grade); 2 mM EGTA; 5 mM MgCl2; adjust pH to 7.6 with KOH, filter strilised). 
The desired concentration of RNA was added and mixed thoroughly. This suspension was 
placed in an electroporation cuvette (0.4cm) and electroporated at 270V and 975μF. In 
order to inhibit secreted IFN neutralizing antibodies against type I IFN was added to the 
freshly electroporated cells. Electroporation efficiency was measure 4 hours post 
electroporation. 
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5.13    Isolation and preparation of nucleic acids 
 
5.13.1 RNA isolation from cells 
RNA  was  isolated  from  eukaryotic  cells  with  the  RNeasy  Mini  Kit  (Qiagen) 
according  to  manufacturer’s  instruction.  This  technology  is  based  on  the selective  
binding properties  of  a  silica-gel-based  membrane.  A specialized high-salt buffer 
system allows up to 100 µg of RNA longer than 200 bases to bind to the  RNeasy  silica-
gel  membrane.  Therefore,  cultured  cells  (~1 *10
7
 cells)  were  first  harvested  and  
homogenized  in  the  presence  of  600  µl  of  a highly    denaturating    guanidine    
isothiocyanate-containing    buffer,    which immediately inactivates RNases to ensure 
isolation of intact RNA. Then, 600 µl of ethanol were added to provide appropriate binding 
conditions. 700 µl of this solution were applied to an RNeasy mini column where the total 
RNA bound to the membrane and contaminants were washed away.  Afterwards, RNA was 
eluted in 50 µl of RNase-free water. 
 
5.13.2 Small scale isolation of plasmid DNA 
Table 7: List of buffers for Plasmid DNA isolation - 
Materials Descrption 
STET buffer          
80 g/L Sucrose, 0.5% Triton X100, 50mM EDTA, 10 mM 
Tris/HCl pH8.0  
TE buffer               0.1 mM EDTA, 10 mM Tris/HCL, pH 8.0   
Lysozyme             10 mg/ml Lysozyme in TE buffer   
Ammonium acetate  8 M NH4OAc   
TE with RNase      10 µg/ml RNase A in TE buffer   
   
2 ml of LB-medium containing the required antibiotic were inoculated with the respective 
E.coli clone and cultured over-night at 37°C, 180 rpm.  Bacterial cell suspensions were 
transferred to 2 ml reaction tubes, centrifuged (6,000 rpm, 2 min) and the supernatant was 
discarded.  Pelleted cells were then re-suspended in 500 µl STET buffer by thorough 
vortexing. After addition of 50 µl lysozyme solution, samples were incubated for 2 - 3 min 
at room temperature for subsequent digestion of the cell walls. The reaction was stopped 
and DNA denatured by heat (95°C, 90 s), subsequent centrifugation (13,000 rpm, 5 min) 
separates genomic DNA that does not renature. The viscous pellets resulting from digested 
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proteins were removed with toothpicks and 50 µl ammonium acetate and 500 µl 
isopropanol were added to the lysate. After centrifugation (13,000 rpm, 5 min) and 
removal of supernatant, the DNA pellet was washed with 500 µl 70% ethanol. Pellets were 
dried thoroughly at 37°C. When transparent, pellets were dissolved in TE + RNase (50 µl).  
 
5.13.3 Large scale isolation of plasmid DNA 
For  large-scale  isolation  of  plasmid  DNA,  the  Plasmid  Maxi  Kit  (Qiagen)  or 
PureYield   Plasmid   Midiprep   (Promega)   kits   were   used   according   to   the 
manufacturer’s instructions. Both technologies base on alkaline lysis of bacteria and 
purification of DNA via silica membranes. 200  –  500  ml  bacterial  suspension  grown  in  
LB-medium  and appropriate antibiotics  at  37°C,  180  rpm  over-night  were  used.  DNA 
was dissolved in appropriate amounts of TE buffer and authenticity checked by agarose gel 
electrophoresis and quantified using a Nanodrop-2000.   
 
5.13.4 Agarose gel electrophoresis 
Table 8: List of buffers for Agarose gel electrophoresis - 
1x TAE buffer: 
40mM Tris acetate (pH 7.5) 20mM Sodium acetate 1mM 
EDTA 
5x loading buffer: 
15% Ficoll, 50mM EDTA, 1X TAE, 0.05% Bromophenol blue, 
0.05% Xylenecyanol 
 
1% agarose gel was made by adding 1gram of agarose to 100ml 1X TAE and bringing to a 
boil in a microwave oven. Once slightly cooled, 2 μl Ethidium bromide or 1.5 μlMidori 
Green was added and the gel was poured into a gel chamber with an appropriate comb in 
place. The set gel was then placed in an electrophoresis tank in 1x TAE buffer.  Prior to 
loading, the DNA samples were mixed with 5x loading buffer. A DNA ladder was loaded 
on the gel to determine the size of the DNA  
 
5.13.5 Purification of DNA from gels 
DNA bands excised from the agarose gels were purified using the QiaQuick gel extraction 
kit from Qiagen according to manufacturer’s instructions. 
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5.13.6 Purification of DNA from PCR samples 
PCR samples were mixed with 3 times PB buffer and then eluted through a column using 
PE buffer as per vendor’s (QiaQuick gel extraction kit from Qiagen ) instructions.  
 
5.13.7 Sequencing 
DNA sequencing was performed by the gene sequencing platform provided by the Gene 
Analysis Department, Helmholtz Centre for Infection Research, Braunschweig. 
 
5.14     DNA modifications 
5.14.1 Restriction analysis of DNA 
Restriction of plasmids and PCR products was performed according to manufacturer’s 
(NEB) instructions on the basis of in-silico digestion on Vector NTI software. 
 
5.14.2 5’ overhang fill ups 
DNA was dissolved in 1X NEBuffer 1 or T4 DNA Ligase Reaction Buffer supplemented 
with 33 μM each dNTP. 1 unit Klenow per microgram DNA was incubated for 15 minutes 
at 25°C. The reaction was stopped by heating at 75°C for 20 minutes.  
 
5.14.3 Site directed Mutagenesis:  
The primers were designed in accordance with the primer design guidelines available at the 
Stratagene website 
(http://www.genomics.agilent.com/CollectionSubpage.aspx?PageType=Tool&SubPageTy
pe=ToolQCPD&PageID=15) and the reactions were performed as per instructions. 
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5.14.4 Dephophorylation of DNA fragments 
 
10 x Phosphatase buffer             
        500 mM Tris/HCl (pH 9.0), 10 mM MgCl 2 , 1 mM  
        ZnCl 2 , 1 mM Spermidine 
   
To  prevent  religation  of  a  restricted  vector,  5’  and  3’  overhanging  ends  were  
dephosphorylated by alkaline phosphatase (shrimp alkaline phosphatase (SAP)  
or calf intestine phosphatase (CIP)). DNA with overhanging ends was incubated  
with 1 x phosphatase buffer and SAP / CIP at 37°C for 30min. The reaction was  
stopped by heat inactivation (20 min at 80°C). 
 
5.14.5 Ligation of DNA fragments 
5 x Ligase buffer 
250  mM  Tris/HCl  (pH7.6),  50  mM  MgCl 2   ,  25%  
(w/v) PEG8000, 5 mM ATP, 5 mM DTT  
 
Ligation of plasmids backbone and insert was performed according to manufacturer’s 
(NEB) instructions on the basis of in-silico digestion on Vector NTI software. A ratio of 
1:10 plasmid: insert was incubated with 1x ligase buffer and 2U T4-DNA Ligase (NEB) in 
a total volume of 10 µl for 3 hours or longer at room temperature. 2 µl of the resulting 
ligation mixture was used for transformation. 
 
5.14.6 Hybridization of oligonucleotides 
 
Annealing buffer 
100mM Potassium acetate, 30mM HEPES-KOH (pH 7.4),    
2mM Magnesium acetate 
 
In order to anneal oligonucleotides, 100pmol/μl of each oligonucleotide was added to 48μl 
of annealing buffer and incubated at 95˚C for 4 minutes. Following this, the reaction was 
incubated at 70˚C for 10 minutes after which it was brought to room temperature and 
stored at 4˚C until further use. 
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5.14.7 Phosphorylation of oligonucleotides 
 
In order to phosphorylate oligonucleotides, 2μl of the desired reaction was incubated in the 
presence of 1μl of T4 Polynucleotide Kinase buffer, 1mM ATP, 1μl of T4 Polynucleotide 
Kinase and 5 μl of double distilled water at 37˚C for 30 minutes followed by a 10 minute 
incubation period at 70˚C. 
 
5.15    Analysis of nucleic acids 
PCR 
PCR  was  carried  out  for  amplifying specific regions of plasmid DNA. Either  
i. BioMix 2x ready mix (Bioline) or 
ii. Expand Long Template PCR system (Roche)   
possessing inherent  3'-5'  exonuclease  or  proof-reading  activity  was  used.  PCR 
comprises a sequence of 3 basic steps that are repeated in 25 - 35 cycles:  
Denaturation: dsDNA    is    melted    to single strands by high temperatures (94 -96°C) 
Annealing: annealing requires lower temperatures for binding of the primers to their 
complementary sequences (temperature is chosen 5 – 10°C below   calculated   melting   
temperature) 
Extension:  involves   synthesis   of complementary   strands   using   the polymerase 
enzyme.  
 
PCR using Expand Long Template System   
Materials Volume 
Supplied PCR buffer (10 x conc) 5µl  
10 (pmol/µl) forward primer          1 µl   
10 (pmol/µl) reverse primer           1 µl   
DMSO         1 – 2.5 µl   
DNA polymerase mix (Roche) (3.75 U)  0.75 µl   
DNA template                 as required   
Water                   upto 50µl   
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PCR program using the T3 thermocycler (Biometra)    
Steps Temperature Time 
1 95 2 min  
2  95 10 sec   
3           58-62 30 sec   
4  72 1 min / kb of product 
5  72 7 min 
6 16 pause 
steps 2 – 4 repeated 25 - 35 times  
 
 
PCR using BioMix (Bioline) (50 µl total)  
Materials Volume 
2 x BioMix 5µl  
10 (pmol/µl) forward primer          1 µl   
10 (pmol/µl) reverse primer           1 µl   
DMSO         2.5 µl 
DNA polymerase mix (Roche) (3.75 U)  0.75 µl   
DNA template                 as required (0.1 – 50 ng) 
Water  up to 50µl   
  
 
PCR program using the T3 thermocycler (Biometra)    
Steps Temperature Time 
1 95 2 min  
2  95 10 sec   
3           58-62 30 sec   
4  72 45 sec / kb of product 
5  72 7 min 
6 16 pause 
steps 2 – 4 repeated 25 - 35 times 
Preparative PCR was carried out in 50 µl, analytical PCR in 20 µl of total volume. 
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5.16 Quantitative real time PCR 
Total cellular RNA was isolated as described above. RNA in a concentration of 100ng/µl 
was added to cDNA ready-to-go first prime tube (GE health care) in the presence of oligo 
dT (0.5µg/3µL) and incubated at 37°C for 1 hour. The resulting cDNA mixture was diluted 
10 times and RT-PCR was carried out to determine induction of IFN stimulated genes 
relative to a house keeping gene Beta-actin.  
 
5.17 NS5B polymerase inhibition assay 
In order to verify if the polymerase competent strain (JFH-1-prom3) could initiate and 
maintain replication after Tet induced transcription, a replication assay in the presence of 
NS5B polymerase inhibitor 2-CMA was performed. To this end, Huh7.5 cells transiently 
transfected with JFH-1-prom3 (POL+) or JFH-1ΔGDD-prom3 was co-transfected with 
lenti tTA and a transfection control vector expressing Renilla luciferase (MDICRluc). 
Upon transfection, the cells were maintained in the absence of Doxycycline for three days 
in order to aid Tet dependent transcription. Following this, the cells were cultured in media 
supplemented with Doxycycline (2μg/ml) in the presence or absence of 3.5μM of NS5B 
polymerase inhibitor 2-CMA. Luciferase values were measured after 29 hours and 39 
hours of incubation. 
 
5.18 Luciferase assays 
Luciferase buffer 
25  mM  glycylglycine,  15  mM  MgSO 4   in  H 2 O,  pH  
7.8 (stored at 4°C)  
ATP solution              5 mM ATP in H 2 O, pH 7.5 (stored at -20°C) 
Luciferin solution 
0.1   mM   synthetic   D-luciferin   (Promega),   25   mM  
glycylglycine in water, pH 7.8 (stored at -20°C)  
Reaction buffer               ATP solution: luciferase buffer (1:5)   
 
Cells  were  washed  with  PBS  and  incubated  with  appropriate  amounts  of passive  
lysis  buffer  (PLB,  Promega)  at  room  temperature  for  15  min,  shaking. For  
luminometric  assay  10  μl  cell  lysate  was  added  to  400  μl  reaction  buffer and 50 μl 
of luciferin were injected at the luminometer, respectively. As firefly luciferase  converts  
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the  substrate  luciferin  in the presence of ATP and oxygen,  light  is emitted and can be 
measured at  610  nm in a luminometer.  Alternatively, lucifersse assays were also 
performed using Firefly luceiferase from Promega. To this end, 20 μl lysate was added to 
100 μl luciferin and the read out was measured at 610 nm. 
 
5.19   Type 1 Interferon detection  
 
5.19.1 VSV inhibition bioassay 
LMTKˉ cells were incubated for 2 hours in the presence of supernatant aspirated from 
electroporated MEFs. Subsequently, cells were infected with VSV-GFP (1.45x10*4 pfu) 
for 1 hour and then incubated in DMEM3+ media for 24 hours. Decrease in GFP 
expression was measured using flow cytometry and was indicative of the antiviral activity 
in the supernatants. 
 
5.19.2 Mx2 reporter IEC 
Intestinal epithelial cells isolated from a reporter mouse expressing luciferase under the 
control of an Mx2 promoter were incubated along with the supernatant aspirated from 
electroporated MEFs. Induction of Mx2 upon IFN stimulation from the supernatant was 
measured as luciferase response. 
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5.20   Flow cytometry 
Antibodies  
Table 9: List of Antibodies - 
 Name Source 
1 Anti-NS3 (HCV) Prof.Thomas Pietschmann, TWINCORE 
2 Anti-NS5A (HCV) Prof.Thomas Pietschmann, TWINCORE 
3 Human NGFR(CD 271) Biolegend 
4 Anti IFN-α (neutralizing) (4EA1) Dr.Lienenklaus, HZI, Braunschweig 
5 Anti IFN-β (neutralizing) (7FD3) Dr.Lienenklaus, HZI, Braunschweig 
 
 
Flow cytometry and cell sorting 
Hepatoma cells stably transfected with the inducible HCV construct along with the 
lentiviral plasmid coding for the transactivator or reverse transactivator were detached 
from plates using trypsin and washed with PBS, stained with antibody  or fixed and 
permeabilized with BD Cytofix/Cytoperm Kit (BD Biosciences).  Cells were stained for an 
hour with antibodies against human NGFR (Biolegend) at 20μg/ml conjugated to PE or 
APC washed twice and re-suspended in FACS buffer. Cell fluorescence was analyzed 
using an LSRII (BD Biosciences) flow cytometer and FlowJo FACS analysis program 
(TreeStar, Ashland, OR).MEFs were detached from plates using trypsin after one wash 
with PBS, the cells were centrifuged and washed using 1x PBS. The pellet was 
resuspended in appropriate volume of FACS buffer. Cells were sorted for GFP positive 
miR-122 cells on the BD FACS Aria. The sorted cells were subsequently cultured in the 
presence of gentamicin sulfate at a final concentration of 1:200 to avoid plausible bacterial 
contamination. 
 
5.21    Stable cell lines 
Huh7.5 and Huh7 cells stably expressing the replication proficient and deficient HCV 
subgenoimc replicon driven by the tet promoter or the newer pTight tet promoter in the 
presence of a transactivator or reverse transactivator were generated by selecting for 
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blasticidin resistant clones. All transfection were carried out using Lipofectamine 2000 
following manufacturer’s instructions along with the co-transfection of a plasmid coding 
for blasticidin resistance. Cells were selected with 7.5μg/ml Blasticidin. The generated 
clones were tested for expression and induction. 
 
5.22    Indirect immunoflourescence 
For immunoflourescence, cells were plated at 2x10^5/ml density on 24 well BD Falcon 
CultureSlides (BD Biosciences, San Jose, CA) and grown overnight at 37°C, 5% CO2.  
Cells were washed with PBS and fixed with 4% paraformaldehyde in a 1:1 ratio for 10 
minutes.  Slides were dried, rinsed with PBS, blocked for 1 hour with 1%Bovine serum 
albumin in PBS in a 1:1 ratio and probed with anti-HCV NS3 antibody in a 1:200 ratio of 
dilution overnight at 4°C.  Slides were washed with 0.5% Tween 20-PBS for 30 min 
followed by staining for FITC goat anti-mouse IgG antibody 1:1000 (Invitrogen) for 1 
hour.  During the final wash step DAPI (2 μg/ml) was added for 10 minutes. Coverslips 
were mounted on a glass slide over a drop of Mowiol and analyzed for fluorescence using 
a Leica microscope. 
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6. Appendix 
qPCR primers-mouse 
 
Primer Name Primer Sequence 
Mu.gbp1-fwd cagggtagacaatgggcagt 
Mu.gbp1-rev cacagtaggctggagcatga 
Mu.mx2-fwd tcaccagagtgcaagtgagg 
Mu.mx2-rev cattctccctctgccacatt 
Mu.Rsad2-fwd gtcctgtttggtgcctgaat 
Mu.Rsad2-rev gccacgcttcagaaacatct 
Mu.isg20-fwd taagcgcctgctacacaaga 
Mu.isg20-rev gcagcttctaaccctggatg 
Mu.usp18-fwd aaggaccagatcacggacac 
Mu.usp18-rev catcctccagggttttcaga 
Mu.irf9-fwd accacggaaccagaaatcac 
Mu.irf9-rev gttgcagttgctgttgctgt 
Mu.beta actin-fwd tggaatcctgtggcatccatgaaa 
Mu.beta actin-rev taaaacgcagctcagtaacagtccg 
Mu.Isg15-fwd gagaggcagcgaactcatct 
Mu.Isg15-rev cttcagctctgacaccgaca 
Mu.Ifit2-fwd gcgtgaagaaggtgaagagg 
Mu.Ifit2-rev gcaggtaggcattgtttggt 
Mu.Viperin-fwd tgcttggtgcctgaatctaa 
Mu.Viperin-rev tttcctcctcgcttcagaaa 
Mu.Usp18-fwd cagaccctgacaatccacct 
Mu.Usp18-rev agctcatactgccctccaga 
Mu.Isg20-fwd gcacaagagcatccagaaca 
Mu.Isg20-rev aagccgaaagcctctagtcc 
Mu.Mx2-fwd aagcagtatcgaggcaagga 
Mu.Mx2-rev tcgtgctctgaacagtttgg 
Mu.IRF9-fwd aggtccagctgtctggaaga 
Mu.IRF9-rev actgtgctgtcgctttgatg 
Mu.IFNbeta-fwd cattacctgaaggccaagga 
Mu.IFNbeta-rev cagcatctgctggttgaaga 
Mu.IFNalfa4-fwd ccagttccagaaggctcaag 
Mu.IFNalfa4-rev agtctcttccaccccaacct 
Mu.Oas-fwd caagctcaagagcctcatcc 
Mu.Oas-rev tgggctgtgttgaaatgtgt 
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qPCR primers-human 
 
Primer Name Primer Sequence 
hAPOBEC3G-fwd ggatgaagcctcacttcaga 
hAPOBEC3G-rev atacacctggcctcgaaag 
h.IFIT3-fwd cagaactgcagggaaacagcc 
h.IFIT4-rev gccaacaagttgtacattgtagc 
h.IFI-6-fwd ctcgctgatgagctggtc 
h.IFI-7-rev ggccaagaaggaagaagagg 
h.ISG15-fwd gagaggcagcgaactcatct 
h.ISG15-rev cttcagctctgacaccgaca 
h.IFIT2/ISG54-fwd gcgtgaagaaggtgaagagg 
h.IFIT2/ISG54-rev gcaggtaggcattgtttggt 
h.IP10/CXCL10-fwd aggaacctccagtctcagca 
h.IP10/CXCL10-rev caaaattggcttgcaggaat 
h.Viperin-fwd tgcttggtgcctgaatctaa 
h.Viperin-rev tttcctcctcgcttcagaaa 
h.USP18-fwd cagaccctgacaatccacct 
h.USP18-rev agctcatactgccctccaga 
h.ISG20-fwd gcacaagagcatccagaaca 
h.ISG20-rev aagccgaaagcctctagtcc 
h.Mx2-fwd aagcagtatcgaggcaagga 
h.Mx2-rev tcgtgctctgaacagtttgg 
h.IRF9-fwd aggtccagctgtctggaaga 
h.IRF9-rev actgtgctgtcgctttgatg 
h.IFN beta1-fwd cattacctgaaggccaagga 
h.IFN beta1-rev cagcatctgctggttgaaga 
h.GBP1-fwd ggtccagttgctgaaagagc 
h.GBP1-rev tgacaggaaggctctggtct 
h.IFN-alpha 4-fwd ccagttccagaaggctcaag 
h.IFN-alpha 4-rev agtctcttccaccccaacct 
h.OAS-fwd caagctcaagagcctcatcc 
h.OAS-rev tgggctgtgttgaaatgtgt 
APPENDIX 
113 
 
h.IRF7 -fwd tacgggtgggcagtagagac 
h.IRF7 -rev ggcccttgtacatgatggtc 
h.IFI6-fwd accttccctgagagccatct 
h.IFI7-rev atctgaggagtgtggggatg 
h.PKR -fwd caaggggaaaacgaaactga 
h.PKR -rev attctgaagaccgccagaga 
Other primers  
HProm_BsaB1fwd AATTCCTGCGATGCAGATCCGG 
HProm_Agerev AATTACCGGTGGATCCTCGCGAGTTTAAACCAG
CTTAGCTTGGCAGAAC 
HPromtTA_Pmel AATTGTTTAAACCACGAGGCCCTTTCGTC 
HPromtTA_BamHl TTAATCGCGACTATAGTGAGTCGTATTACCTGC
AGGGGCCGCGGAGGCTGG 
Hprom5U_BamH1 AATTGGATCCACCTGCCCCTAATAGGGG 
Hprom5U_Age1 AATTCACCGGTTCCGCAGACCAC 
Hsel_Age AATTGAACCGGTGAGTACACCG 
Hsel_Not AATTGCGCGGCCGCTTACAATTTG 
miR122for AATTCCCTTAGCAGAGCTGTGGAGTGTGACAAT
GGTGTTTGTGTCTAAACTATCAAACGCCATTAT
CACACTAAATAGCTACTGCTAGGCG 
miR122rev GATCCGCCTAGCAGTAGCTATTTAGTGTGATAA
TGGCGTTTGATAGTTTAGACACAAACACCATTG
TCACACTCCACAGCTCTGCTAAGGG 
 
 
 
Plasmid vectors 
 JFH-1prom3 and JFH-1ΔGDDprom3 
The plasmid was designed to make the subgenoimc replicon pFKi389 NS3JFH1 or the 
pFKi389 NS3JFH1ΔGDD encoding the genotype2a strain into a tet regulatable system. To 
this end, an intermediate plasmid cloned HCVprom3. 
The helper vector was cloned by performing a PCR on the pFKi389 NS3 JFH1 vector to 
amplify a 321bp region before the T7 promter using primers HProm_BsaB1 and 
HProm_Age. This vector was the used to embed a PCR amplified pTBC-1 vector carrying 
the Tet promoter using primers HPromtTA_PmeI and HPromtTA_BamHI. Following this, 
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PCR derived 5’ NTR using primers HProm5U_BamHI and HProm5U_Age from the 
pFKi389 NS3 JFH1 vector was embedded. This vector is referred to as the HCV prom3. 
PmeI and AgeI restricted HCV prom3 vector was ligated to a PmeI and AgeI restricted 
pFKi389 NS3 JFH1 or pFKi389 NS3JFH1ΔGDD. 
 JFH-1pTight and JFH-1ΔGDDpTight 
The helper vector was cloned by performing a PCR on the pFKi389 NS3JFH1 or the 
pFKi389 NS3JFH1ΔGDD vector to amplify a 321bp region before the T7 promter. This 
vector was the used to embed a PCR amplified pTRE-Tight vector carrying the Tet 
promoter. Following this, PCR derived 5’ NTR from the pFKi389 NS3 JFH1 vector was 
embedded. This vector is referred to as the HCV pTight. PmeI and AgeI restricted HCV 
prom3 vector was ligated to a PmeI and AgeI restricted pFKi389 NS3JFH1 or the pFKi389 
NS3JFH1ΔGDD. 
 
 SIEW-miR122 
Oligos coding for miR122-f and miR122-r were phosphorylated and hybridized with each 
other. Plasmid pSuperΔEΔB was restricted with ECoRI and BamHI and ligated to the 
annealed oligos. The miR122 and the surrounding miR-30 was PCR amplified from the 
resulting vector pSuperΔEΔB-miR122 with BglII flanking primers and ligated into BamHI 
restricted lentiviral vector SIEW. 
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6.3 Abbreviations 
 
 
α    alpha  
β    beta  
γ    gamma  
δ    delta  
ε   epsilon  
κ    kappa  
λ    lambda  
μ   micro  
A    adenosine  
APC   antigen presenting cell  
ATP   adenosintriphoshate  
bp    base pair  
BSA   bovine serum albumin 
C    cytosine  
CARD   caspase recruitment domain  
cDNA   complementary DNA  
CMV   cytomegalovirus  
Da    dalton  
DAA   direct-acting antiviral 
DC   dendritic cell  
DMEM  Dulbecco's modified Eagle's medium  
DNA   deoxyribonucleicacid  
dNTP   deoxyribonucleotidetriphosphate  
dsRNA   double-stranded RNA  
E. coli   Escherichia coli  
eGFP   enhanced GFP  
eIF-2   eukaryotic initiation factor-2 
FBS   fetal bovine serum   
F-luc   Firefly luciferase 
G    guanidine  
G418   aminoglycoside-2´-deoxystreptin  
GFP    green fluorescent protein  
GMP   guanosine monophosphate  
GTPase   guanosine triphosphatase  
h    hours  
HAU   haem agglutinating unit  
HCC   hepato cellular carcinoma 
HCV   hepatitis-C virus 
HMG   high-mobility group  
ICSBP   IFN consensus sequence binding protein  
IFN    interferon  
IFNAR  interferon-α/β receptor 
IKK    inhibitor of NF-κB kinase  
IL    interleukin  
IPS-1   IFN-β promoter stimulator  
IRF    IFN regulatory factor  
IRFE   IRF-element  
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ISG   IFN stimulated gene 
ISGF   IFN stimulated gene factor  
ISRE   IFN stimulated response elements  
JAK    Janus activated kinase  
JFH-1  Japanese fulminant hepatitis-1 
Kn    kanamycin  
LGP-2   laboratory of genetics and physiology-2  
LPS    lipopolysaccharide  
Luc    luciferase  
m    milli  
M    molarity  
Mda5  melanoma-differentiation-associated gene 5  
MEF   mouse embryonic fibroblast  
MHC  major histocompatibility complex  
min    minute  
mRNA   messenger RNA  
miR-122  MicroRNA-122 
miRISC  miRNA-induced silencing complex 
MOI   multiplicity of infection 
Mx    myxovirus resistance gene  
MyD88   myeloid differentiation factor gene 88  
n    nano  
NANB  non A non B 
NDV   Newcastle disease virus  
nptII    neomycin phosphotransferase  
NF-κB   nuclear factor κB  
NTR   non-translated region 
OAS    oligoadenylate synthetase  
OD    optical density  
ORF    open reading frame  
PAMP  pathogen-associated molecular pattern  
PBS    phosphate buffered saline  
PCR    polymerase chain reaction  
PGK    phosphoglycerate kinase  
PKR    protein kinase R  
PLB    passive lysis buffer  
poly I:C   polyinosinic-polycytidylic acid  
PRD    positive regulatory domain  
PRR    pathogen recognition receptor  
qPCR   quantitative PCR  
RIG-I   retinoic-acid-inducible gene I  
RLH    RIG-I-like helicases  
RLU   relative light units 
RNA   ribonucleic acid  
RNase   ribonuclease  
Rt-PCR   reverse transcriptase PCR  
s   second  
SDS    sodium dodecyl sulfate  
SOCS   suppressor of cytokine signalling  
SNP   single nucleotide polymorphism 
STAT   signal transducer and activator of transcription  
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STING   stimulator of IFN genes  
SR-B1  scavenger receptor class B type I 
SV40   simian virus 40  
T    thymidine  
TBK-1  TANK-binding kinase 1   
Tet    tetracycline  
TIR    Toll/interleukin-1 receptor homology 
TLR    toll-like receptor  
TNFα   tumor necrosis factor alpha  
TRAF3   TNF-receptor associated factor 3  
TRIF   TIR-domain containing adaptor inducing IFN-β 
TRIM25   tripartite-motif containing protein 25  
Tris    tris-hydroxymethyl-aminomethan  
Tyk2   tyrosin kinase 2  
U    unit  
USP-18  ubiquitin-specific peptidase 18 
VSV    vesicular stomatitis virus  
WT   wild type 
 
 
Latinisms are written in italics. 
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